IP/N/1/EU/U/2  
 
12 April 2013  
(13-1946)  Page: 1/35  
Council for Trade-Related Aspects 
of Intellectual Property Rights  Original: English/anglais/inglés  
 
 MAIN DEDICATED INTELLECTUAL PROPERTY LAWS AND 
REGULATIONS NOTIFIED UNDER ARTICLE 63.2 
OF THE AGREEMENT 
EUROPEAN UNION 
This document reproduces the text1 of Regulation (EC) No 726/2004 of the European Parliament 
and of the Council of 31 March 2004 laying down Community procedures for the authorisation and 
supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, as notified by the European Union on 20 March 2013 under Article 63.2 of the 
Agreement (see document IP/N/1/EU/1).  
Conseil des aspects des droits de propriété 
intellectuelle qui touchent au commerce 
PRINCIPALES LOIS ET RÉGLEMENTATIONS CONSACRÉES À 
LA PROPRIÉTÉ INTELLECTUELLE NOTIFIÉES AU TITRE 
DE L'ARTICLE 63:2 DE L'ACCORD 
UNION EUROPÉENNE  
Le présent document contient le texte1 du Règlement (CE) n° 726/2004 du Parlement européen et 
du Conseil du 31 mars 2004 établissant des procédures communautaires pour l'autorisation et la 
surveillance en ce qui concerne les médicaments à usage humain et à usage vétérinaire, et instituant une Agence européenne des médicaments, notifié par l'Union européenne le 
20 mars 2013 au titre de l'article 63:2 de l'Accord (voir le document IP/N/1/EU/1).  
Consejo de los Aspectos de los Derechos de Propiedad Intelectual relacionados con el Comercio 
PRINCIPALES LEYES Y REGLAMENTOS DEDICADOS A LA 
PROPIEDAD INTELECTUAL NOTIFICADOS EN VIRTUD 
DEL PÁRRAFO 2 DEL ARTÍCULO 63 DEL ACUERDO 
 U
NIÓN EUROPEA  
En el presente documento se reproduce el texto1 del Reglamento (CE) Nº 726/2004 del 
Parlamento Europeo y el Consejo, de 31 de  marzo de 2004, por el que se establecen 
procedimientos comunitarios para la autorización y el control de medicamentos de uso humano y 
veterinario y por el que se crea la Agencia Europea de Medicamentos, notificado por la Unión Europea el 20 de marzo de 2013 en virtud de lo dispuesto en el párrafo 2 del artículo 63 del 
Acuerdo (véase el documento IP/N/1/EU/1).  
                                               
1 In English only./En anglais seulement./En inglés solamente. IP/N/1/EU/U/2 
 
- 2 - 
 
  PP 3-35 - Offset (Pdf file attached) 
PP 3 à 35 - Offset (fichier Pdf joint) PP 3-35 - Offset (fichero Pdf adjunto) I
(Acts whose publication is obligatory)
REGULATION (EC) No 726/2004 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
of 31 March 2004
laying down Community procedures for the authorisation and supervision of medicinal products
for human and veterinary use and establishing a European Medicines Agency
(Text with EEA relevance)
THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE
EUROPEAN UNION,
Having regard to the Treaty establishing the European
Community, and in particular Article 95 and Article152(4)(b) thereof,
Having regard to the proposal from the Commission (
1),
Having regard to the Opinion of the European Economic and
Social Committee (2),
After consulting the Committee of the Regions,
In accordance with the procedure laid down in Article 251 of
the Treaty (3),
Whereas:
(1) Article 71 of Council Regulation (EEC) No 2309/93 of
22 July 1993 laying down Community procedures forthe authorisation and supervision of medicinal productsfor human and veterinary use and establishing aEuropean Agency for the Evaluation of MedicinalProducts (
4) provides that, within six years of the entry
into force of the Regulation, the Commission is to
publish a general report on the experience acquired as
a result of the operation of the procedures laid down in
the Regulation.
(2) In the light of the Commission's report on theexperience gained, it has proved necessary to improvethe operation of the authorisation procedures for the
placing of medicinal products on the market in theCommunity and to amend certain administrativeaspects of the European Agency for the Evaluation ofMedicinal Products. In addition, the name of thatAgency should be simplified and changed to theEuropean Medicines Agency, (hereinafter referred to as
the ‘Agency’).
(3) It emerges from the conclusions of that report that the
amendments to be made to the centralised procedure setup by Regulation (EEC) No 2309/93 consist ofcorrections to some of the operating procedures andadaptations to take account of the probable devel-opment of science and technology and the futureenlargement of the European Union. It also emergesfrom the report that the general principles previouslyestablished which govern the centralised procedure
should be maintained.
(4) Moreover, since the European Parliament and the
Council have adopted Directive 2001/83/EC of6 November 2001 on the Community code relating tomedicinal products for human use (
5) and Directive
2001/82/EC of 6 November 2001 on the Communitycode relating to veterinary medicinal products (
6), all the
references to the codified Directives in Regulation (EEC)No 2309/93 should be updated.
(5) For the sake of clarity, it is necessary to replace the saidRegulation with a new Regulation.
(6) It is appropriate to preserve the Community mechanismset up by the repealed Community legislation for
concertation prior to any national decision relating to
a high-technology medicinal product.EN 30.4.2004 Official Journal of the European Union L 136/1
(1) OJ C 75 E, 26.3.2002, p. 189 and OJ C . . . (not yet published in
the Official Journal).
(2) OJ C 61, 14.3.2003, p. 1.
(3) Opinion of the European Parliament of 23 October 2002 (OJ C
300 E, 11.12.2003, p. 308), Council Common Position of
29 September 2003 (OJ C 297 E, 9.12.2003, p. 1), Position ofthe European Parliament of 17 December 2003 (not yet
published in the Official Journal) and Council Decision of
11 March 2004.
(
4) OJ L 214, 24.8.1993, p. 1. Regulation as last amended by Regu-
lation (EC) No 1647/2003 (OJ L 245, 29.9.2003, p. 19).(5) OJ L 311, 28.11.2001, p. 67. Directive as last amended by Council
Directive 2004/27/EC (see p. 34 of this Official Journal).
(6) OJ L 311, 28.11.2001, p. 1. Directive as amended by Council
Directive 2004/28/EC (see p. 58 of this Official Journal).
IP/N/1/EU/U/2 
        - 3 -(7) Experience gained since the adoption of Council
Directive 87/22/EEC of 22 December 1986 on theapproximation of national measures relating to theplacing on the market of high-technology medicinalproducts, particularly those derived from biotech-nology (
1) has shown that it is necessary to create a
centralised authorisation procedure that is compulsory
for high-technology medicinal products, particularly
those resulting from biotechnical processes, in order to
maintain the high level of scientific evaluation of thesemedicinal products in the European Union and thus topreserve the confidence of patients and the medicalprofessions in the evaluation. This is particularlyimportant in the context of the emergence of newtherapies, such as gene therapy and associated celltherapies, and xenogenic somatic therapy. Thisapproach should be maintained, particularly with aview to ensuring the effective operation of the internalmarket in the pharmaceutical sector.
(8) With a view to harmonising the internal market for newmedicinal products, this procedure should also be madecompulsory for orphan medicinal products and anymedicinal product for human use containing anentirely new active substance, i.e. one that has not yetbeen authorised in the Community, and for which thetherapeutic indication is the treatment of acquiredimmune deficiency syndrome, cancer, neurodegenerativedisorder or diabetes. Four years after the date of entryinto force of this Regulation, the procedure should alsobecome compulsory for medicinal products for humanuse containing a new active substance, and for whichthe therapeutic indication is for the treatment of auto-
immune diseases and other immune dysfunctions and
viral diseases. It should be possible to review theprovisions in point 3 of the Annex via a simplifieddecision-making procedure not earlier than four yearsafter the entry into force of this Regulation.
(9) As regards medicinal products for human use, optionalaccess to the centralised procedure should also be
provided for in cases where use of a single procedure
produces added value for the patient. This procedureshould remain optional for medicinal products which,although not belonging to the abovementionedcategories, are nevertheless therapeutically innovative.It is also appropriate to allow access to this procedurefor medicinal products which, although not innovative,may be of benefit to society or to patients if they areauthorised from the outset at Community level, such ascertain medicinal products which can be suppliedwithout a medical prescription. This option may beextended to generic medicinal products authorised bythe Community, provided that this in no wayundermines either the harmonisation achieved whenthe reference medicinal product was evaluated or theresults of that evaluation.
(10) In the field of veterinary medicinal products, adminis-trative measures should be laid down in order to takeaccount of the specific features of this field, particularlythose due to the regional distribution of certain diseases.It should be possible to use the centralised procedure forthe authorisation of veterinary medicinal products usedwithin the framework of Community provisions
regarding prophylactic measures for epizootic diseases.
Optional access to the centralised procedure should bemaintained for veterinary medicinal products containinga new active substance.
(11) For medicinal products for human use, the period forprotection of data relating to pre-clinical tests andclinical trials should be the same as that provided forin Directive 2001/83/EC. For medicinal products forveterinary use, the period for protection of datarelating to pre-clinical tests and clinical trials as wellas safety and residue tests should be the same as thatprovided for in Directive 2001/82/EC.
(12) In order to reduce the cost for small and medium-sizedenterprises of marketing medicinal products authorisedvia the centralised procedure, provisions should beadopted to allow for a reduction of fees, deferring thepayment of fees, taking over responsibility for trans-lations and offering administrative assistance in respectof these enterprises.
(13) In the interest of public health, authorisation decisionsunder the centralised procedure should be taken on thebasis of the objective scientific criteria of quality, safety
and efficacy of the medicinal product concerned, to the
exclusion of economic and other considerations.However, Member States should be able exceptionallyto prohibit the use in their territory of medicinalproducts for human use which infringe objectivelydefined concepts of public policy and public morality.Moreover, a veterinary medicinal product is not to beauthorised by the Community if its use wouldcontravene the rules laid down within the frameworkof the Common Agricultural Policy or if presented fora use prohibited under other Community provisions,inter alia Directive 96/22/EC (
2).
(14) Provision should be made for the quality, safety andefficacy criteria in Directives 2001/83/EC and2001/82/EC to apply to medicinal products authorisedby the Community and it should be possible to assessthe risk-benefit balance of all medicinal products whenthey are placed on the market, at the time of the
renewal of the authorisation and at any other time the
competent authority deems appropriate.EN L 136/2 Official Journal of the European Union 30.4.2004
(1) OJ L 15, 17.1.1987, p. 38. Directive repealed by Directive
93/41/EEC (OJ L 214, 24.8.1993, p. 40).(2) Council Directive 96/22/EC of 29 April 1996 concerning the
prohibition on the use in stockfarming of certain substances
having a hormonal or thyrostatic action and of β-agonists (OJ L
125, 23.5.1996, p. 3).
IP/N/1/EU/U/2 
        - 4 -(15) The Community is required, pursuant to Article 178 of
the Treaty, to take account of the development policyaspects of any measure and to promote the creation ofconditions fit for human beings worldwide. Phar-maceutical law should continue to ensure that only effi-cacious, safe and top-quality medicinal products areexported, and the Commission should considercreating further incentives to carry out research into
medicinal products against widespread tropical diseases.
(16) There is also a need to provide for the ethical
requirements of Directive 2001/20/EC of 4 April 2001of the European Parliament and of the Council on theapproximation of the laws, regulations and adminis-trative provisions of the Member States relating to theimplementation of good clinical practice in the conductof clinical trials on medicinal products for human use (
1)
to apply to medicinal products authorised by theCommunity. In particular, with respect to clinical trialsconducted outside the Community on medicinalproducts destined to be authorised within the
Community, at the time of the evaluation of the
application for authorisation, it should be verified thatthese trials were conducted in accordance with the prin-ciples of good clinical practice and the ethicalrequirements equivalent to the provisions of the saidDirective.
(17) The Community should have the means to carry out ascientific assessment of the medicinal products presentedin accordance with the decentralised Community auth-orisation procedures. Moreover, with a view to ensuringthe effective harmonisation of administrative decisionstaken by Member States with regard to medicinal
products presented in accordance with decentralised
authorisation procedures, it is necessary to endow theCommunity with the means to resolve disagreementsbetween Member States concerning the quality, safetyand efficacy of medicinal products.
(18) The structure and operation of the various bodiesmaking up the Agency should be designed in such away as to take into account the need constantly torenew scientific expertise, the need for cooperationbetween Community and national bodies, the need foradequate involvement of civil society, and the futureenlargement of the European Union. The various
bodies of the Agency should establish and develop
appropriate contacts with the parties concerned, inparticular representatives of patients and health-careprofessionals.
(19) The chief task of the Agency should be to provideCommunity institutions and Member States with thebest possible scientific opinions so as to enable themto exercise the powers regarding the authorisation andsupervision of medicinal products conferred on them byCommunity legislation in the field of medicinalproducts. Only after a single scientific evaluationprocedure addressing the quality, safety and efficacy ofhigh-technology medicinal products has been conductedby the Agency, applying the highest possible standards,
should marketing authorisation be granted by the
Community, and this should be done by means of arapid procedure ensuring close cooperation betweenthe Commission and Member States.
(20) In order to ensure close cooperation between theAgency and scientists operating in Member States, thecomposition of the Management Board should be suchas to guarantee that the competent authorities of theMember States are closely involved in the overallmanagement of the Community system for authorisingmedicinal products.
(21) The Agency's budget should be composed of fees paidby the private sector and contributions paid out of theCommunity budget to implement Community policies.
(22) Paragraph 25 of the Interinstitutional Agreement of6 May 1999 between the European Parliament, theCouncil and the Commission on budgetary disciplineand improvement of budgetary procedure (
2) provides
for the Financial Perspective to be adjusted in order to
cover the new needs resulting from enlargement.
(23) Exclusive responsibility for preparing the Agency's
opinions on all questions concerning medicinalproducts for human use should be vested in aCommittee for Medicinal Products for Human Use. Asfar as veterinary medicinal products are concerned, suchresponsibility should be vested in a Committee forMedicinal Products for Veterinary Use. As regardsorphan medicinal products, the task should fall to theCommittee on Orphan Medicinal Products set up underRegulation (EC) No 141/2000 of the European
Parliament and of the Council of 16 December 1999
on orphan medicinal products (
3). Lastly, as regards
herbal medicinal products, this responsibility should bevested in the Committee on Herbal Medicinal Productsset up under Directive 2001/83/EC.
(24) The creation of the Agency will make it possible toreinforce the scientific role and independence of thecommittees, particularly through the setting-up of apermanent technical and administrative secretariat.EN 30.4.2004 Official Journal of the European Union L 136/3
(1) OJ L 121, 1.5.2001, p. 34.(2) OJ C 172, 18.6.1999, p. 1.
(3) OJ L 18, 22.1.2000, p. 1.
IP/N/1/EU/U/2 
        - 5 -(25) The field of activity of the Scientific Committees should
be enlarged and their operating methods andcomposition modernised. Scientific advice for futureapplicants seeking marketing authorisation should beprovided more generally and in greater depth. Similarly,structures allowing the development of advice forcompanies, in particular small and medium-sized enter-prises, should be put in place. The committees should be
able to delegate some of their evaluation duties to
standing working parties open to experts from thescientific world appointed for this purpose, whilstretaining total responsibility for the scientific opinionsissued. The re-examination procedures should beamended to provide a better guarantee for applicants'rights.
(26) The number of members of the Scientific Committeesparticipating in the centralised procedure should beestablished with a view to ensuring that the committees
remain of an efficient size after the enlargement of the
European Union.
(27) It is also necessary to reinforce the role of the ScientificCommittees in such a way as to enable the Agency toparticipate actively in international scientific dialogueand to develop certain activities that will be necessary,in particular regarding international scientific harmon-isation and technical cooperation with the WorldHealth Organisation.
(28) Furthermore, in order to create greater legal certainty itis necessary to define the responsibilities regarding thetransparency rules for the Agency's work, to set certainconditions for the marketing of medicinal products auth-orised by the Community, to confer on the Agencypowers to monitor the distribution of medicinalproducts authorised by the Community and to specifythe sanctions and the procedures for implementing themin the event of failure to observe the provisions of thisRegulation and the conditions contained in the author-isations granted under the procedures it establishes.
(29) It is also necessary to take measures for the supervisionof medicinal products authorised by the Community,and in particular for the intensive supervision of unde-sirable effects of these medicinal products within theframework of Community pharmacovigilance activities,so as to ensure the rapid withdrawal from the market ofany medicinal product presenting a negative risk-benefitbalance under normal conditions of use.
(30) In order to enhance the efficiency of market surveillance,the Agency should be responsible for coordinatingMember States' pharmacovigilance activities. A numberof provisions need to be introduced to put in placestringent and efficient pharmacovigilance procedures,
to allow the competent authority to take provisionalemergency measures, including the introduction ofamendments to the marketing authorisation and,finally, to permit a reassessment to be made at anytime of the risk-benefit balance of a medicinal product.
(31) It is also appropriate to entrust the Commission, in closecooperation with the Agency and after consultationswith the Member States, with the task of coordinatingthe execution of the various supervisory responsibilitiesvested in the Member States, and in particular with thetasks of providing information on medicinal productsand of checking the observance of good manufacturing,laboratory and clinical practices.
(32) It is necessary to provide for the coordinated implemen-
tation of Community procedures for the authorisation of
medicinal products, and of the national procedures ofMember States which have already been harmonised to aconsiderable degree by Directives 2001/83/EC and2001/82/EC. It is appropriate that the operation of theprocedures laid down by this Regulation be re-examinedby the Commission every ten years on the basis ofexperience gained.
(33) In order to meet, in particular, the legitimate expec-tations of patients and to take account of theincreasingly rapid progress of science and therapies,accelerated assessment procedures should be set up,
reserved for medicinal products of major therapeutic
interest, and procedures for obtaining temporary auth-orisations subject to certain annually reviewableconditions. In the field of medicinal products forhuman use, a common approach should also befollowed, whenever possible, regarding the criteria andconditions for the compassionate use of new medicinalproducts under Member States' legislation.
(34) Member States have developed an evaluation of thecomparative efficacy of medicinal products aimed atpositioning a new medicinal product with respect tothose that already exist in the same therapeutic class.
Similarly, the Council, in its Conclusions on medicinal
products and public health (
1), adopted on 29 June
2000, emphasised the importance of identifying
medicinal products that presented an added therapeuticvalue. However this evaluation should not be conductedin the context of the marketing authorisation, for whichit is agreed that the fundamental criteria should beretained. It is useful in this respect to allow for thepossibility of gathering information on the methodsused by the Member States to determine the therapeuticbenefit obtained by each new medicinal product.EN L 136/4 Official Journal of the European Union 30.4.2004
(1) OJ C 218, 31.7.2000, p. 10.
IP/N/1/EU/U/2 
        - 6 -(35) In line with the current provisions of Directives
2001/83/EC and 2001/82/EC, the term of validity of aCommunity marketing authorisation should be limitedinitially to a period of five years, upon the expiry ofwhich it should be renewed. Thereafter the marketingauthorisation should normally be of unlimited validity.Furthermore, any authorisation not used for threeconsecutive years, that is to say, one which has not
led to the placing on the market of a medicinal
product in the Community during that period, shouldbe considered invalid, in order, in particular, to avoidthe administrative burden of maintaining such authoris-ations. However, this rule should be subject toexemptions when these are justified on public healthgrounds.
(36) Environmental risks may arise from medicinal productscontaining or consisting of genetically modifiedorganisms. It is thus necessary to subject suchproducts to an environmental risk-assessmentprocedure similar to the procedure under Directive2001/18/EC of the European Parliament and of theCouncil of 12 March 2001 on the deliberate releaseinto the environment of genetically modifiedorganisms (
1), to be conducted in parallel with the
evaluation, under a single Community procedure, of
the quality, safety and efficacy of the product concerned.
(37) The measures necessary for the implementation of thisRegulation should be adopted in accordance withCouncil Decision 1999/468/EC of 28 June 1999 layingdown the procedures for the exercise of implementingpowers conferred on the Commission (
2).
(38) The provisions of Regulation (EC) No 1647/2003 (3)
amending Regulation (EC) No 2309/93 as regards the
budgetary and financial rules applicable to the Agencyand access to the Agency's documents should be fullyincorporated into this Regulation,
HAVE ADOPTED THIS REGULATION:
TITLE I
DEFINITIONS AND SCOPE
Article 1
The purpose of this Regulation is to lay down Community
procedures for the authorisation, supervision and phar-macovigilance of medicinal products for human and veterinaryuse, and to establish a European Medicines Agency (hereinafterreferred to as ‘the Agency’).
The provisions of this Regulation shall not affect the powers of
Member States' authorities as regards setting the prices ofmedicinal products or their inclusion in the scope of thenational health system or social security schemes on thebasis of health, economic and social conditions. In particular,Member States shall be free to choose from the particularsshown in the marketing authorisation those therapeutic indi-cations and pack sizes which will be covered by their socialsecurity bodies.
Article 2
The definitions laid down in Article 1 of Directive 2001/83/ECand those laid down in Article 1 of Directive 2001/82/EC shallapply for the purposes of this Regulation.
The holder of a marketing authorisation for medicinal products
covered by this Regulation must be established in theCommunity. The holder shall be responsible for the placingon the market of those medicinal products, whether he doesit himself or via one or more persons designated to that effect.Article 3
1. No medicinal product appearing in the Annex may be
placed on the market within the Community unless amarketing authorisation has been granted by the Communityin accordance with the provisions of this Regulation.
2. Any medicinal product not appearing in the Annex may
be granted a marketing authorisation by the Community inaccordance with the provisions of this Regulation, if:
(a) the medicinal product contains a new active substance
which, on the date of entry into force of this Regulation,
was not authorised in the Community; or
(b) the applicant shows that the medicinal product constitutes
a significant therapeutic, scientific or technical innovationor that the granting of authorisation in accordance withthis Regulation is in the interests of patients or animalhealth at Community level.
Immunological veterinary medicinal products for the treatmentof animal diseases that are subject to Community prophylacticmeasures may also be granted such authorisation.
___________
(1) OJ L 106, 17.4.2001, p. 1. Directive as last amended by Regulation
(EC) No 1830/2003 of the European Parliament and of the Council
(OJ L 268, 18.10.2003, p. 24).
(2) OJ L 184, 17.7.1999, p. 23.
(3) OJ L 245, 29.9.2003, p. 19.EN 30.4.2004 Official Journal of the European Union L 136/5
IP/N/1/EU/U/2 
        - 7 -3. A generic medicinal product of a reference medicinal
product authorised by the Community may be authorised bythe competent authorities of the Member States in accordancewith Directive 2001/83/EC and Directive 2001/82/EC underthe following conditions:
(a) the application for authorisation is submitted in accordance
with Article 10 of Directive 2001/83/EC or Article 13 of
Directive 2001/82/EC;
(b) the summary of the product characteristics is in all relevant
respects consistent with that of the medicinal product auth-
orised by the Community except for those parts of the
summary of product characteristics referring to indications
or dosage forms which were still covered by patent law atthe time when the generic medicine was marketed; and
(c) the generic medicinal product is authorised under the same
name in all the Member States where the application has
been made. For the purposes of this provision, all thelinguistic versions of the INN (international non-proprietaryname) shall be considered to be the same name.4. After the competent committee of the Agency has been
consulted, the Annex may be re-examined in the light oftechnical and scientific progress, with a view to making anynecessary amendments without extending the scope of thecentralised procedure. Such amendments shall be adopted inaccordance with the procedure referred to in Article 87(2).
Article 4
1. Applications for the marketing authorisations referred to
in Article 3 shall be submitted to the Agency.
2. The Community shall grant and supervise marketing
authorisations for medicinal products for human use inaccordance with Title II.
3. The Community shall grant and supervise marketing
authorisations for veterinary medicinal products in accordancewith Title III.
TITLE II
AUTHORISATION AND SUPERVISION OF MEDICINAL PRODUCTS FOR HUMAN USE
Chapter 1
Submission and examination of applications —
Authorisations
Article 5
1. A Committee for Medicinal Products for Human Use ishereby established. The Committee shall be part of the Agency.
2. Without prejudice to Article 56 or to other tasks which
Community law may confer on it, the Committee for MedicinalProducts for Human Use shall be responsible for drawing upthe opinion of the Agency on any matter concerning the
admissibility of the files submitted in accordance with the
centralised procedure, the granting, variation, suspension orrevocation of an authorisation to place a medicinal productfor human use on the market in accordance with theprovisions of this Title, and pharmacovigilance.
3. At the request of the Executive Director of the Agency or
the Commission representative, the Committee for Medicinal
Products for Human Use shall also draw up an opinion on anyscientific matter concerning the evaluation of medicinalproducts for human use. The Committee shall take dueaccount of any requests by Member States for an opinion.The Committee shall also formulate an opinion wheneverthere is disagreement in the evaluation of medicinal productsthrough the mutual recognition procedure. The opinion of theCommittee shall be made publicly accessible.Article 6
1. Each application for the authorisation of a medicinal
product for human use shall specifically and completely
include the particulars and documents as referred to inArticles 8(3), 10, 10a, 10b or 11 of, and Annex I to,Directive 2001/83/EC. The documents must include astatement to the effect that clinical trials carried out outsidethe European Union meet the ethical requirements of Directive2001/20/EC. These particulars and documents shall takeaccount of the unique, Community nature of the authorisationrequested and, otherwise than in exceptional cases relating tothe application of the law on trade marks, shall include the useof a single name for the medicinal product.
The application shall be accompanied by the fee payable to the
Agency for the examination of the application.
2. In the case of a medicinal product for human use
containing or consisting of genetically modified organismswithin the meaning of Article 2 of Directive 2001/18/EC, theapplication shall be accompanied by:
(a) a copy of the competent authorities' written consent to the
deliberate release into the environment of the genetically
modified organisms for research and development purposeswhere provided for in Part B of Directive 2001/18/EC or inPart B of Council Directive 90/220/EEC of 23 April 1990
on the deliberate release into the environment of
genetically modified organisms (
1);EN L 136/6 Official Journal of the European Union 30.4.2004
(1) OJ L 117, 8.5.1990, p. 15. Directive repealed by Directive
2001/18/EC, but continues to have certain legal effects.
IP/N/1/EU/U/2 
        - 8 -(b) the complete technical dossier supplying the information
required by Annexes III and IV to Directive 2001/18/EC;
(c) the environmental risk assessment in accordance with the
principles set out in Annex II to Directive 2001/18/EC; and
(d) the results of any investigations performed for the purposes
of research or development.
Articles 13 to 24 of Directive 2001/18/EC shall not apply to
medicinal products for human use containing or consisting ofgenetically modified organisms.
3. The Agency shall ensure that the opinion of the
Committee for Medicinal Products for Human Use is givenwithin 210 days after receipt of a valid application.
The duration of the analysis of the scientific data in the file
concerning the application for marketing authorisation must beat least 80 days, except in cases where the rapporteur andco-rapporteur declare that they have completed theirassessment before that time.
On the basis of a duly reasoned request, the said Committee
may call for the duration of the analysis of the scientific data inthe file concerning the application for marketing authorisationto be extended.
In the case of a medicinal product for human use containing or
consisting of genetically modified organisms, the opinion of the
said Committee shall respect the environmental safety
requirements laid down by Directive 2001/18/EC. During theprocess of evaluating applications for marketing authorisationsfor medicinal products for human use containing or consistingof genetically modified organisms, the rapporteur shall carryout necessary consultations of bodies that the Community orMember States have set up in accordance with Directive2001/18/EC.
4. The Commission shall, in consultation with the Agency,
Member States and interested parties, draw up a detailed guideregarding the form in which applications for authorisation areto be presented.
Article 7
In order to prepare its opinion, the Committee for Medicinal
Products for Human Use:
(a) shall verify that the particulars and documents submitted in
accordance with Article 6 comply with the requirements of
Directive 2001/83/EC, and shall examine whether theconditions specified in this Regulation for granting amarketing authorisation are satisfied;(b) may request that an Official Medicines Control Laboratory
or a laboratory that a Member State has designated for thatpurpose test the medicinal product for human use, itsstarting materials and, if need be, its intermediateproducts or other constituent materials in order to ensurethat the control methods employed by the manufacturerand described in the application documents are satisfactory;
(c) may request that the applicant supplement the particulars
accompanying the application within a specific time period.
Where the said Committee avails itself of this option, thetime-limit laid down in Article 6(3), first subparagraph,shall be suspended until such time as the supplementaryinformation requested has been provided. Likewise, thistime-limit shall be suspended for the time allowed for theapplicant to prepare oral or written explanations.
Article 8
1. Upon receipt of a written request from the Committee for
Medicinal Products for Human Use, a Member State shallforward the information showing that the manufacturer of amedicinal product or the importer from a third country is ableto manufacture the medicinal product concerned and/or carryout the necessary control tests in accordance with theparticulars and documents supplied pursuant to Article 6.
2. Where it considers it necessary in order to complete its
examination of an application, the said Committee may requirethe applicant to undergo a specific inspection of the manu-
facturing site of the medicinal product concerned. Such
inspections may be made unannounced.
The inspection shall be carried out within the time-limit laid
down in the first subparagraph of Article 6(3) by inspectorsfrom the Member State holding the appropriate qualifications;they may be accompanied by a rapporteur or an expertappointed by the Committee.
Article 9
1. The Agency shall forthwith inform the applicant if theopinion of the Committee for Medicinal Products for HumanUse is that:
(a) the application does not satisfy the criteria for author-
isation set out in this Regulation;
(b) the summary of the product characteristics proposed by the
applicant needs to be amended;
(c) the labelling or package leaflet of the product is not in
compliance with Title V of Directive 2001/83/EC;
(d) the authorisation needs to be granted subject to the
conditions provided for in Article 14(7) and (8).EN 30.4.2004 Official Journal of the European Union L 136/7
IP/N/1/EU/U/2 
        - 9 -2. Within 15 days after receipt of the opinion referred to in
paragraph 1, the applicant may give written notice to theAgency that he wishes to request a re-examination of theopinion. In that case, the applicant shall forward to theAgency the detailed grounds for the request within 60 daysafter receipt of the opinion.
Within 60 days following receipt of the grounds for the
request, the said Committee shall re-examine its opinion inaccordance with the conditions laid down in the fourthsubparagraph of Article 62(1). The reasons for the conclusionreached shall be annexed to the final opinion.
3. Within 15 days after its adoption, the Agency shall send
the final opinion of the said Committee to the Commission, to
the Member States and to the applicant, together with a report
describing the assessment of the medicinal product by theCommittee and stating the reasons for its conclusions.
4. If an opinion is favourable to the granting of the relevant
authorisation to place the medicinal product concerned on themarket, the following documents shall be annexed to theopinion:
(a) a draft summary of the product characteristics, as referred
to in Article 11 of Directive 2001/83/EC;
(b) details of any conditions or restrictions which should be
imposed on the supply or use of the medicinal product
concerned, including the conditions under which themedicinal product may be made available to patients, inaccordance with the criteria laid down in Title VI ofDirective 2001/83/EC;
(c) details of any recommended conditions or restrictions with
regard to the safe and effective use of the medicinalproduct;
(d) the draft text of the labelling and package leaflet proposed
by the applicant, presented in accordance with Title V ofDirective 2001/83/EC;
(e) the assessment report.
Article 10
1. Within 15 days after receipt of the opinion referred to inArticle 5(2), the Commission shall prepare a draft of thedecision to be taken in respect of the application.
Where a draft decision envisages the granting of a marketing
authorisation, it shall include or make reference to thedocuments mentioned in Article 9(4)(a), (b), (c) and (d).
Where the draft decision is not in accordance with the opinion
of the Agency, the Commission shall annex a detailed expla-nation of the reasons for the differences.The draft decision shall be forwarded to Member States and theapplicant.
2. The Commission shall take a final decision in accordance
with, and within 15 days after the end of, the procedurereferred to in Article 87(3).
3. The Standing Committee on Medicinal Products for
Human Use referred to in Article 87(1) shall adjust its rulesof procedure so as to take account of the tasks incumbentupon it under this Regulation.
The adjustments shall provide that:(a) the opinion of the said Standing Committee is to be given
in writing;
(b) Member States shall have 22 days to forward their written
observations on the draft decision to the Commission.
However, if a decision has to be taken urgently, a shortertime-limit may be set by the Chairman according to the
degree of urgency involved. This time-limit shall not,
otherwise than in exceptional circumstances, be shorterthan 5 days;
(c) Member States may request in writing that the draft
decision referred to in paragraph 1 be discussed by aplenary meeting of the said Standing Committee, statingtheir reasons in detail.
4. Where, in the opinion of the Commission, a Member
State's written observations raise important new questions ofa scientific or technical nature which the opinion delivered bythe Agency has not addressed, the Chairman shall suspend theprocedure and refer the application back to the Agency forfurther consideration.
5. The Commission shall adopt the provisions necessary for
the implementation of paragraph 4 in accordance with theprocedure referred to in Article 87(2).
6. The Agency shall disseminate the documents referred to
in Article 9(4)(a), (b), (c) and (d).
Article 11
If an applicant withdraws an application for a marketing auth-
orisation submitted to the Agency before an opinion has beengiven on the application, the applicant shall communicate itsreasons for doing so to the Agency. The Agency shall makethis information publicly accessible and shall publish theassessment report, if available, after deletion of all informationof a commercially confidential nature.EN L 136/8 Official Journal of the European Union 30.4.2004
IP/N/1/EU/U/2 
        - 10 -Article 12
1. The marketing authorisation shall be refused if, after
verification of the particulars and documents submitted inaccordance with Article 6, it appears that the applicant hasnot properly or sufficiently demonstrated the quality, safetyor efficacy of the medicinal product.
Authorisation shall likewise be refused if particulars or
documents provided by the applicant in accordance with
Article 6 are incorrect or if the labelling and package leaflet
proposed by the applicant are not in accordance with Title Vof Directive 2001/83/EC.
2. The refusal of a Community marketing authorisation shall
constitute a prohibition on the placing on the market of themedicinal product concerned throughout the Community.
3. Information about all refusals and the reasons for them
shall be made publicly accessible.
Article 13
1. Without prejudice to Article 4(4) of Directive
2001/83/EC, a marketing authorisation which has beengranted in accordance with this Regulation shall be validthroughout the Community. It shall confer the same rightsand obligations in each of the Member States as a marketing
authorisation granted by that Member State in accordance with
Article 6 of Directive 2001/83/EC.
Authorised medicinal products for human use shall be entered
in the Community Register of Medicinal Products and shall begiven a number, which shall appear on the packaging.
2. Notification of marketing authorisation shall be published
in the Official Journal of the European Union , quoting in
particular the date of authorisation and the registrationnumber in the Community Register, any InternationalNon-proprietary Name (INN) of the active substance of themedicinal product, its pharmaceutical form, and anyAnatomical Therapeutic Chemical Code (ATC).
3. The Agency shall immediately publish the assessment
report on the medicinal product for human use drawn up bythe Committee for Medicinal Products for Human Use and thereasons for its opinion in favour of granting authorisation, afterdeletion of any information of a commercially confidentialnature.
The European Public Assessment Report (EPAR) shall include a
summary written in a manner that is understandable to thepublic. The summary shall contain in particular a sectionrelating to the conditions of use of the medicinal product.4. After a marketing authorisation has been granted, theholder of the authorisation shall inform the Agency of thedates of actual marketing of the medicinal product forhuman use in the Member States, taking into account thevarious presentations authorised.
The holder shall also notify the Agency if the product ceases to
be placed on the market, either temporarily or permanently.Such notification shall, otherwise than in exceptional circum-stances, be made no less than 2 months before the interruptionin the placing on the market of the product.
Upon request by the Agency, particularly in the context of
pharmacovigilance, the marketing authorisation holder shallprovide the Agency with all data relating to the volume ofsales of the medicinal product at Community level, brokendown by Member State, and any data in the holder's possessionrelating to the volume of prescriptions.
Article 14
1. Without prejudice to paragraphs 4, 5 and 7 a marketing
authorisation shall be valid for five years.
2. The marketing authorisation may be renewed after five
years on the basis of a re-evaluation by the Agency of therisk-benefit balance.
To this end, the marketing authorisation holder shall provide
the Agency with a consolidated version of the file in respect ofquality, safety and efficacy, including all variations introducedsince the marketing authorisation was granted, at least sixmonths before the marketing authorisation ceases to be validin accordance with paragraph 1.
3. Once renewed, the marketing authorisation shall be valid
for an unlimited period, unless the Commission decides, onjustified grounds relating to pharmacovigilance, to proceedwith one additional five-year renewal in accordance withparagraph 2.
4. Any authorisation which is not followed by the actual
placing of the medicinal product for human use on theCommunity market within three years after authorisationshall cease to be valid.
5. When an authorised medicinal product previously placed
on the market is no longer actually present on the market forthree consecutive years, the authorisation shall cease to bevalid.
6. In exceptional circumstances and on public health
grounds the Commission may grant exemptions fromparagraphs 4 and 5. Such exemptions must be duly justified.EN 30.4.2004 Official Journal of the European Union L 136/9
IP/N/1/EU/U/2 
        - 11 -7. Following consultation with the applicant, an author-
isation may be granted subject to certain specific obligations,to be reviewed annually by the Agency. The list of these obli-gations shall be made publicly accessible.
By way of derogation from paragraph 1, such authorisation
shall be valid for one year, on a renewable basis.
The provisions for granting such authorisation shall be laid
down in a Commission Regulation adopted in accordancewith the procedure referred to in Article 87(2).
8. In exceptional circumstances and following consultation
with the applicant, the authorisation may be granted subject toa requirement for the applicant to introduce specificprocedures, in particular concerning the safety of themedicinal product, notification to the competent authoritiesof any incident relating to its use, and action to be taken.This authorisation may be granted only for objective, verifiablereasons and must be based on one of the grounds set out in
Annex I to Directive 2001/83/EC. Continuation of the author-
isation shall be linked to the annual reassessment of theseconditions.
9. When an application is submitted for a marketing auth-
orisation in respect of medicinal products for human use whichare of major interest from the point of view of public healthand in particular from the viewpoint of therapeutic innovation,the applicant may request an accelerated assessment procedure.The request shall be duly substantiated.
If the Committee for Medicinal Products for Human Use
accepts the request, the time-limit laid down in Article 6(3),first subparagraph, shall be reduced to 150 days.
10. When adopting its opinion, the Committee for
Medicinal Products for Human Use shall include a proposalconcerning the criteria for the prescription or use of themedicinal products in accordance with Article 70(1) ofDirective 2001/83/EC.
11. Without prejudice to the law on the protection of
industrial and commercial property, medicinal products forhuman use which have been authorised in accordance withthe provisions of this Regulation shall benefit from aneight-year period of data protection and a ten-year period ofmarketing protection, in which connection the latter periodshall be extended to a maximum of 11 years if, during thefirst eight years of those ten years, the marketing authorisationholder obtains an authorisation for one or more new thera-peutic indications which, during the scientific evaluation priorto their authorisation, are held to bring a significant clinical
benefit in comparison with existing therapies.
Article 15
The granting of authorisation shall not affect the civil or
criminal liability of the manufacturer or of the holder of themarketing authorisation pursuant to the applicable national law
in Member States.
Chapter 2
Supervision and penalties
Article 16
1. After an authorisation has been granted in accordance
with this Regulation, the holder of the marketing authorisationfor a medicinal product for human use shall, in respect of themethods of manufacture and control provided for in Article
8(3)(d) and (h) of Directive 2001/83/EC, take account of
technical and scientific progress and make any variations thatmay be required to enable the medicinal products to be manu-factured and checked by means of generally accepted scientificmethods. He shall apply for approval of such variations inaccordance with this Regulation.
2. The holder of the marketing authorisation shall forthwith
supply to the Agency, to the Commission and to the MemberStates any new information which might entail the variation ofthe particulars or documents referred to in Articles 8(3), 10,10a, 10b and 11 of Directive 2001/83/EC, in Annex I thereto,or in Article 9(4) of this Regulation.
In particular, he shall forthwith inform the Agency, the
Commission and the Member States of any prohibition orrestriction imposed by the competent authorities of anycountry in which the medicinal product for human use ismarketed and of any other new information which mightinfluence the evaluation of the benefits and risks of themedicinal product for human use concerned.
In order that the risk-benefit balance may be continuously
assessed, the Agency may at any time ask the holder of themarketing authorisation to forward data demonstrating that therisk-benefit balance remains favourable.
3. If the holder of the authorisation for a medicinal product
for human use proposes to make any variation of theparticulars and documents referred to in paragraph 2, heshall submit the relevant application to the Agency.
4. The Commission shall, after consulting the Agency, adopt
appropriate provisions for the examination of variations tomarketing authorisations in the form of a regulation inaccordance with the procedure referred to in Article 87(2).
Article 17
The applicant or the holder of a marketing authorisation shallbe responsible for the accuracy of the documents and of thedata submitted.EN L 136/10 Official Journal of the European Union 30.4.2004
IP/N/1/EU/U/2 
        - 12 -Article 18
1. In the case of medicinal products for human use manu-
factured within the Community, the supervisory authoritiesshall be the competent authorities of the Member State orMember States which granted the manufacturing authorisationprovided for in Article 40(1) of Directive 2001/83/EC inrespect of the medicinal product concerned.
2. In the case of medicinal products imported from third
countries, the supervisory authorities shall be the competentauthorities of the Member State or Member States that grantedthe authorisation provided for in Article 40(3) of Directive2001/83/EC to the importer, unless appropriate agreementshave been made between the Community and the exportingcountry to ensure that those controls are carried out in theexporting country and that the manufacturer applies standardsof good manufacturing practice at least equivalent to those laiddown by the Community.
A Member State may request assistance from another Member
State or from the Agency.
Article 19
1. The supervisory authorities shall be responsible forverifying on behalf of the Community that the holder of themarketing authorisation for the medicinal product for humanuse or the manufacturer or importer established within theCommunity satisfies the requirements laid down in Titles IV,
IX and XI of Directive 2001/83/EC.
2. Where, in accordance with Article 122 of Directive
2001/83/EC, the Commission is informed of serious differencesof opinion between Member States as to whether the holder ofthe marketing authorisation for the medicinal product forhuman use or a manufacturer or importer established withinthe Community satisfies the requirements referred to inparagraph 1, the Commission may, after consultation withthe Member States concerned, request an inspector from thesupervisory authority to undertake a new inspection of themarketing authorisation holder, the manufacturer or theimporter; the inspector in question shall be accompanied bytwo inspectors from Member States which are not party to thedispute or by two experts nominated by the Committee forMedicinal Products for Human Use.
3. Subject to any agreements which may have been
concluded between the Community and third countries in
accordance with Article 18(2), the Commission may,
following a reasoned request from a Member State or fromthe said Committee, or on its own initiative, require a manu-facturer established in a third country to submit to aninspection.
The inspection shall be undertaken by inspectors from the
Member States who possess the appropriate qualifications;they may be accompanied by a rapporteur or expertappointed by the said Committee. The report of the inspectorsshall be made available to the Commission, the Member Statesand the said Committee.
Article 20
1. Where the supervisory authorities or the competent auth-
orities of any other Member State are of the opinion that themanufacturer or importer established within the Communityterritory is no longer fulfilling the obligations laid down inTitle IV of Directive 2001/83/EC, they shall forthwith informthe Committee for Medicinal Products for Human Use and theCommission, stating their reasons in detail and indicating thecourse of action proposed.
The same shall apply where a Member State or the
Commission considers that one of the measures envisaged inTitles IX and XI of Directive 2001/83/EC should be applied inrespect of the medicinal product concerned or where the saidCommittee has delivered an opinion to that effect inaccordance with Article 5 of this Regulation.
2. The Commission shall request the opinion of the Agency
within a time-limit which it shall determine in the light of theurgency of the matter, in order to examine the reasonsadvanced. Whenever practicable, the holder of the author-isation for placing the medicinal product for human use onthe market shall be invited to provide oral or written expla-nations.
3. Following an opinion by the Agency, the Commission
shall adopt the necessary provisional measures, which shallbe applied immediately.
A final decision shall be adopted within six months, in
accordance with the procedure referred to in Article 87(3).
4. Where urgent action is essential to protect human health
or the environment, a Member State may, on its own initiativeor at the Commission's request, suspend the use in its territory
of a medicinal product for human use which has been auth-
orised in accordance with this Regulation.
When it does so on its own initiative, it shall inform the
Commission and the Agency of the reasons for its action at
the latest on the next working day following the suspension.The Agency shall inform the other Member States withoutdelay. The Commission shall immediately initiate theprocedure provided for in paragraphs 2 and 3.
5. In this case, the Member State shall ensure that
health-care professionals are rapidly informed of its actionand the reasons for the action. Networks set up by professionalassociations may be used to this effect. The Member Statesshall inform the Commission and the Agency of actionstaken for this purpose.EN 30.4.2004 Official Journal of the European Union L 136/11
IP/N/1/EU/U/2 
        - 13 -6. The suspensive measures referred to in paragraph 4 may
be maintained in force until such time as a definitive decisionhas been reached in accordance with the procedure referred toin Article 87(3).
7. The Agency shall, upon request, inform any person
concerned of the final decision and make the decisionpublicly accessible immediately after it has been taken.
Chapter 3
Pharmacovigilance
Article 21
For the purposes of this Chapter, Article 106(2) of Directive2001/83/EC shall apply.
Article 22
The Agency, acting in close cooperation with the national
pharmacovigilance systems established in accordance withArticle 102 of Directive 2001/83/EC, shall receive all relevantinformation concerning suspected adverse reactions tomedicinal products for human use which have been authorisedby the Community in accordance with this Regulation. Whereappropriate, the Committee for Medicinal Products for HumanUse shall, in accordance with Article 5 of this Regulation, drawup opinions on the measures necessary. These opinions shallbe made publicly accessible.
The measures referred to in the first paragraph may include
amendments to the marketing authorisation granted inaccordance with Article 10. They shall be adopted inaccordance with the procedure referred to in Article 87(3).
The holder of the marketing authorisation and the competent
authorities of Member States shall ensure that all relevantinformation concerning suspected adverse reactions to themedicinal products authorised under this Regulation arebrought to the attention of the Agency in accordance withthe provisions of this Regulation. Patients shall be encouragedto communicate any adverse reaction to health-careprofessionals.
Article 23
The holder of an authorisation for a medicinal product for
human use granted in accordance with the provisions of thisRegulation shall have permanently and continuously at hisdisposal an appropriately qualified person responsible for phar-macovigilance.
That qualified person shall reside in the Community and shall
be responsible for the following:
(a) establishing and managing a system which ensures that
information concerning all suspected adverse reactionswhich are reported to the personnel of the company and
to medical representatives is collected, evaluated andcollated so that it may be accessed at a single pointwithin the Community;
(b) preparing the reports referred to in Article 24(3) for the
competent authorities of the Member States and the
Agency in accordance with the requirements of this Regu-lation;
(c) ensuring that any request from the competent authorities
for the provision of additional information necessary for
the evaluation of the risks and benefits of a medicinal
product is answered fully and promptly, including theprovision of information regarding the volume of sales orprescriptions for the medicinal product concerned;
(d) providing the competent authorities with any other
information relevant to the evaluation of the risks and
benefits of a medicinal product, particularly informationconcerning post-authorisation safety studies.
Article 24
1. The holder of the marketing authorisation for a medicinal
product for human use shall ensure that all suspected serious
adverse reactions to a medicinal product authorised in
accordance with this Regulation occurring within theCommunity which a health-care professional brings to hisattention are recorded and reported promptly to MemberStates within the territory of which the incident occurred,and no later than 15 days following the receipt of theinformation.
The holder of the marketing authorisation shall record any
other suspected serious adverse reactions occurring withinthe Community, in accordance with the guide referred to inArticle 26, of which he may reasonably be expected to beaware, and promptly notify the competent authority ofMember States in the territory of which the incidentoccurred and the Agency, and no later than 15 daysfollowing receipt of the information.
2. The holder of the marketing authorisation for a medicinal
product for human use shall ensure that all suspected seriousunexpected adverse reactions and any suspected transmissionvia a medicinal product of any infectious agent occurring in
the territory of a third country are reported promptly to
Member States and the Agency, and no later than 15 daysfollowing receipt of the information. The provisions for thereporting of suspected unexpected adverse reactions whichare not serious, whether occurring in the Community or in athird country, shall be adopted in accordance with theprocedure referred to in Article 87(2).
Save in exceptional circumstances, these reactions shall be
transmitted electronically in the form of a report and inaccordance with the guide referred to in Article 26.EN L 136/12 Official Journal of the European Union 30.4.2004
IP/N/1/EU/U/2 
        - 14 -3. The holder of the marketing authorisation for a medicinal
product for human use shall maintain detailed records of allsuspected adverse reactions within or outside the Communitywhich are reported to him by a health-care professional.
Unless other requirements have been laid down as a condition
for the granting of the marketing authorisation by theCommunity, these records shall be submitted, in the form ofa periodic safety update report, to the Agency and MemberStates immediately upon request or at least every six monthsafter authorisation until the placing on the market. Periodicsafety update reports shall also be submitted immediatelyupon request or at least every six months during the firsttwo years following the initial placing on the Communitymarket and once a year for the following two years. Thereafter,the reports shall be submitted at three-yearly intervals, orimmediately upon request.
These reports shall be accompanied by a scientific evaluation,
particularly of the risk-benefit balance of the medicinalproduct.
4. The Commission may lay down provisions to amend
paragraph 3 in view of experience gained with its operation.The Commission shall adopt any such provisions in accordancewith the procedure referred to in Article 87(2).
5. The holder of a marketing authorisation may not
communicate information relating to pharmacovigilanceconcerns to the general public in relation to its authorisedmedicinal product without giving prior or simultaneous notifi-cation to the Agency.
In any case, the marketing authorisation holder shall ensure
that such information is presented objectively and is not
misleading.
Member States shall take the necessary measures to ensure that
a marketing authorisation holder who fails to discharge theseobligations is subject to effective, proportionate and dissuasivepenalties.
Article 25
Each Member State shall ensure that all suspected seriousadverse reactions occurring within their territory to amedicinal product for human use authorised in accordancewith this Regulation which are brought to their attention arerecorded and reported promptly to the Agency and themarketing authorisation holder, and no later than 15 daysfollowing receipt of the information.
The Agency shall forward the information to the national phar-
macovigilance systems set up in accordance with Article 102of Directive 2001/83/EC.Article 26
The Commission, in consultation with the Agency, Member
States and interested parties, shall draw up a guide on thecollection, verification and presentation of adverse-reactionreports. This guide shall contain, in particular, for the benefitof health-care professionals, recommendations concerning thecommunication of information on adverse reactions.
In accordance with this guide, holders of marketing authoris-
ations shall use the medical terminology accepted at inter-national level for the transmission of adverse-reaction reports.
The Agency, in consultation with Member States and the
Commission, shall set up a data-processing network for therapid transmission of information to the competentCommunity authorities in the event of an alert relating to
faulty manufacture, serious adverse reactions and other phar-
macovigilance data regarding medicinal products authorised inaccordance with Article 6 of Directive 2001/83/EC. Such datashall be made publicly accessible, if relevant, after evaluation.
For a period of five years following the initial placing on the
market in the Community, the Agency may request that themarketing authorisation holder arrange for specific phar-
macovigilance data to be collected from targeted groups of
patients. The Agency shall state the reasons for the request.The marketing authorisation holder shall collate and assess thedata collected and submit it to the Agency for evaluation.
Article 27
The Agency shall collaborate with the World Health Organi-sation in matters of international pharmacovigilance and shalltake the necessary steps to submit to it, promptly, appropriateand adequate information regarding the measures taken in theCommunity which may have a bearing on public healthprotection in third countries; it shall send a copy thereof tothe Commission and the Member States.
Article 28
The Agency and Member States' competent authorities shall
cooperate to continuously develop pharmacovigilance systemscapable of achieving high standards of public health protection
for all medicinal products, regardless of routes of authorisation,
including the use of collaborative approaches, to maximise useof resources available within the Community.
Article 29
Any amendment which may be necessary to update the
provisions of this Chapter in order to take account of scientificand technical progress shall be adopted in accordance with theprocedure referred to in Article 87(2).EN 30.4.2004 Official Journal of the European Union L 136/13
IP/N/1/EU/U/2 
        - 15 -TITLE III
AUTHORISATION AND SUPERVISION OF VETERINARY MEDICINAL PRODUCTS
Chapter 1
Submission and examination of applications —
Authorisations
Article 30
1. A Committee for Medicinal Products for Veterinary Use is
hereby established. The Committee shall be part of the Agency.
2. Without prejudice to Article 56 and other tasks which
Community law may confer on it, in particular under Regu-lation (EEC) No 2377/90 (
1), the Committee for Medicinal
Products for Veterinary Use shall be responsible for drawing
up the opinion of the Agency on any question concerning theadmissibility of files submitted in accordance with thecentralised procedure, the granting, variation, suspension orrevocation of an authorisation to place a veterinary medicinalproduct on the market arising in accordance with theprovisions of this Title, and pharmacovigilance.
3. At the request of the Executive Director of the Agency or
the Commission representative, the Committee for MedicinalProducts for Veterinary Use shall also draw up opinions on anyscientific matters concerning the evaluation of veterinarymedicinal products. The Committee shall take due account ofany requests from Member States for an opinion. TheCommittee shall also formulate an opinion whenever there isdisagreement in the assessment of a veterinary medicinalproduct through the mutual recognition procedure. Theopinion of the Committee shall be made publicly accessible.
Article 31
1. Each application for the authorisation of a medicinalproduct for veterinary use shall specifically and exhaustivelyinclude the particulars and documents as referred to inArticles 12(3), 13, 13a, 13b and 14 of, and Annex I to,Directive 2001/82/EC. These particulars and documents shalltake account of the unique, Community nature of the author-isation requested and, otherwise than in exceptional casesrelating to the application of the law on trade marks, shall
include the use of a single name for the medicinal product.
The application shall be accompanied by the fee payable to the
Agency for the examination of the application.
2. In the case of a veterinary medicinal product containing
or consisting of genetically modified organisms within themeaning of Article 2 of Directive 2001/18/EC, the applicationshall also be accompanied by:(a) a copy of the written consent of the competent authorities
to the deliberate release into the environment of the
genetically modified organisms for research and devel-opment purposes, as provided for in Part B of Directive2001/18/EC or in Part B of Directive 90/220/EEC;
(b) the complete technical file supplying the information
required under Annexes III and IV to Directive
2001/18/EC;
(c) the environmental risk assessment in accordance with the
principles set out in Annex II to Directive 2001/18/EC; and
(d) the results of any investigations performed for the purposes
of research or development.
Articles 13 to 24 of Directive 2001/18/EC shall not apply to
veterinary medicinal products containing or consisting ofgenetically modified organisms.
3. The Agency shall ensure that the opinion of the
Committee for Medicinal Products for Veterinary Use is givenwithin 210 days after the receipt of a valid application.
In the case of a veterinary medicinal product containing or
consisting of genetically modified organisms, the opinion ofthe said Committee must respect the environmental safetyrequirements laid down by Directive 2001/18/EC. During theprocess of evaluating applications for marketing authorisationsfor veterinary medicinal products containing or consisting ofgenetically modified organisms, necessary consultations shall beheld by the rapporteur with the bodies set up by theCommunity or the Member States in accordance withDirective 2001/18/EC.
4. The Commission shall, in consultation with the Agency,
Member States and interested parties, draw up a detailed guideregarding the form in which applications for authorisation areto be presented.
Article 32
1. In order to prepare its opinion, the Committee forMedicinal Products for Veterinary Use:
(a) shall verify that the particulars and documents submitted in
accordance with Article 31 comply with the requirements
of Directive 2001/82/EC and examine whether theconditions specified in this Regulation for granting amarketing authorisation are satisfied;EN L 136/14 Official Journal of the European Union 30.4.2004
(1) Council Regulation (EEC) No 2377/90 of 26 June 1990 laying
down a Community procedure for the establishment of maximum
residue limits of veterinary medicinal products in foodstuffs of
animal origin (OJ L 224, 18.8.1990, p. 1). Regulation as lastamended by Commission Regulation (EC) No 1029/2003 (OJ L149, 17.6.2003, p. 15).
IP/N/1/EU/U/2 
        - 16 -(b) may request that an Official Medicines Control Laboratory
or a laboratory that a Member State has designated for that
purpose test the veterinary medicinal product, its startingmaterials and, where appropriate, its intermediate productsor other constituent materials in order to ensure that thecontrol methods employed by the manufacturer anddescribed in the application are satisfactory;
(c) may request a Community reference laboratory, Official
Medicines Control Laboratory or laboratory that a
Member State has designated for that purpose to verify,using samples provided by the applicant, that the analyticaldetection method proposed by the applicant for the
purposes of Article 12(3)(j), second indent, of Directive
2001/82/EC is satisfactory and is suitable for use toreveal the presence of residue levels, particularly thoseabove the maximum residue level accepted by theCommunity in accordance with the provisions of Regu-lation (EEC) No 2377/90;
(d) may request the applicant to supplement the particulars
accompanying the application within a specific time-limit.Where the said Committee avails itself of this option, thetime-limit laid down in Article 31(3), first subparagraphshall be suspended until such time as the supplementaryinformation requested has been provided. Likewise, thetime-limit shall be suspended for the time allowed to theapplicant to prepare oral or written explanations.
2. In those cases where the analytical method has not beensubject to verification by one of the abovementioned labora-tories under the procedures established by Regulation (EEC)No 2377/90, the verification shall be carried out within theframework of this Article.
Article 33
1. Upon receipt of a written request from the Committee for
Medicinal Products for Veterinary Use, a Member State shall
forward the information establishing that the manufacturer of a
veterinary medicinal product or the importer from a thirdcountry is able to manufacture the veterinary medicinalproduct concerned and/or carry out the necessary controltests in accordance with the particulars and documentssupplied pursuant to Article 31.
2. Where it considers it necessary in order to complete its
examination of the application, the said Committee mayrequire the applicant to undergo a specific inspection of themanufacturing site of the veterinary medicinal productconcerned. Such inspections may be made unannounced.
The inspection, which shall be completed within the time-limit
referred to in Article 31(3), first subparagraph, shall beundertaken by inspectors from the Member State whopossess the appropriate qualifications; they may be accom-panied by a rapporteur or expert appointed by the saidCommittee.Article 34
1. The Agency shall forthwith inform the applicant if theopinion of the Committee for Medicinal Products forVeterinary Use is that:
(a) the application does not satisfy the criteria for author-
isation set out in this Regulation;
(b) the summary of the product characteristics should be
amended;
(c) the labelling or package leaflet of the product is not in
compliance with Title V of Directive 2001/82/EC;
(d) the authorisation should be granted subject to the
conditions provided for in Article 39(7).
2. Within 15 days after receipt of the opinion referred to in
paragraph 1, the applicant may provide written notice to theAgency that he wishes to request a re-examination of theopinion. In that case the applicant shall forward to theAgency the detailed grounds for the request within 60 daysafter receipt of the opinion.
Within 60 days after receipt of the grounds for the request, the
said Committee shall re-examine its opinion in accordance withthe conditions laid down in Article 62(1), fourth subparagraph.The reasons for the conclusion reached shall be annexed to thefinal opinion.
3. Within 15 days after its adoption, the Agency shall
forward the final opinion of the said Committee to theCommission, to Member States and to the applicant, togetherwith a report describing the assessment of the veterinarymedicinal product by the Committee and stating the reasonsfor its conclusions.
4. If an opinion is favourable to the granting of the relevant
authorisation to place the relevant veterinary medicinal producton the market, the following documents shall be annexed tothe opinion:
(a) a draft summary of the product characteristics, as referred
to in Article 14 of Directive 2001/82/EC; where appro-
priate, this draft shall reflect differences in the veterinary
conditions in the Member States;
(b) in the case of a veterinary medicinal product intended for
administration to food-producing animals, a statement of
the maximum residue level which may be accepted by theCommunity in accordance with Regulation (EEC)No 2377/90;EN 30.4.2004 Official Journal of the European Union L 136/15
IP/N/1/EU/U/2 
        - 17 -(c) details of any conditions or restrictions which should be
imposed on the supply or use of the veterinary medicinal
product concerned, including the conditions under whichthe veterinary medicinal product may be made available tousers, in conformity with the criteria laid down in Directive2001/82/EC;
(d) details of any recommended conditions or restrictions with
regard to the safe and effective use of the medicinal
product;
(e) the draft text of the labelling and package leaflet proposed
by the applicant, presented in accordance with Title V of
Directive 2001/82/EC;
(f) the assessment report.
Article 35
1. Within 15 days after receipt of the opinion referred to in
Article 30(2), the Commission shall prepare a draft of thedecision to be taken in respect of the application.
Where a draft decision envisages the granting of marketing
authorisation, it shall include or make reference to thedocuments mentioned in Article 34(4)(a) to (e).
Where the draft decision is not in accordance with the opinion
of the Agency, the Commission shall annex a detailed expla-nation of the reasons for the differences.
The draft decision shall be forwarded to Member States and the
applicant.
2. The Commission shall take a final decision in accordance
with, and within 15 days after the end of, the procedurereferred to in Article 87(3).
3. The Standing Committee for Veterinary Medicinal
Products referred to in Article 87(1) shall adjust its rules of
procedure so as to take account of the tasks assigned to it by
this Regulation.
The adjustments shall provide that:(a) the opinion of the said Standing Committee is to be given
in writing;
(b) Member States shall have 22 days to forward their written
observations on the draft decision to the Commission;
however, if a decision has to be taken urgently, a shortertime-limit may be set by the Chairman according to thedegree of urgency involved. This time-limit shall not,otherwise than in exceptional circumstances, be shorterthan 5 days;(c) Member States may request in writing that the draft
decision referred to in paragraph 1 be discussed at aplenary meeting of the said Standing Committee, statingtheir reasons in detail.
4. Where, in the opinion of the Commission, the writtenobservations of a Member State raise important new questionsof a scientific or technical nature which have not beenaddressed in the opinion delivered by the Agency, theChairman shall suspend the procedure and refer the applicationback to the Agency for further consideration.
5. The provisions necessary for the implementation of
paragraph 4 shall be adopted by the Commission inaccordance with the procedure referred to in Article 87(2).
6. The Agency shall disseminate the documents referred to
in Article 34(4) (a) to (e).
Article 36
If an applicant withdraws an application for a marketing auth-orisation submitted to the Agency before an opinion has beengiven on the application, the applicant shall communicate itsreasons for doing so to the Agency. The Agency shall makethis information publicly accessible and shall publish theassessment report, if available, after deletion of all informationof a commercially confidential nature.
Article 37
1. The marketing authorisation shall be refused if, after
verification of the particulars and documents submitted inaccordance with Article 31, it appears that:
(a) the applicant has not properly or sufficiently demonstrated
the quality, safety or efficacy of the veterinary medicinal
product;
(b) in the case of zootechnical veterinary medicinal products
and performance enhancers, when the safety and welfare of
the animals and/or consumer safety have not beensufficiently taken into account;
(c) the withdrawal period recommended by the applicant is
not long enough to ensure that foodstuffs obtained fromtreated animals do not contain residues which mightconstitute a health hazard for the consumer or is insuf-ficiently substantiated;
(d) the veterinary medicinal product is presented for a use
prohibited under other Community provisions.
Authorisation shall likewise be refused if particulars ordocuments provided by the applicant in accordance withArticle 31 are incorrect or if the labelling and packageleaflets proposed by the applicant are not in accordance withTitle V of Directive 2001/82/EC.EN L 136/16 Official Journal of the European Union 30.4.2004
IP/N/1/EU/U/2 
        - 18 -2. The refusal of a Community marketing authorisation shall
constitute a prohibition on the placing on the market of theveterinary medicinal product concerned throughout theCommunity.
3. Information about all refusals and the reasons for them
shall be made publicly accessible.
Article 38
1. Without prejudice to Article 71 of Directive 2001/82/EC,a marketing authorisation which has been granted inaccordance with this Regulation shall be valid throughout theCommunity. It shall confer the same rights and obligations ineach of the Member States as a marketing authorisationgranted by that Member State in accordance with Article 5of Directive 2001/82/EC.
Authorised veterinary medicinal products shall be entered in
the Community Register of Medicinal Products and shall be
given a number which shall appear on the packaging.
2. Notification of marketing authorisation shall be published
in the Official Journal of the European Union , quoting in
particular the date of authorisation and the number in the
Community Register, any International Non-proprietary Name(INN) of the active substance of the medicinal product, itspharmaceutical form, and any Anatomical TherapeuticChemical Veterinary Code (ATC Vet Code).
3. The Agency shall immediately publish the assessment
report on the veterinary medicinal product drawn up by theCommittee for Medicinal Products for Veterinary Use and thereasons for its opinion in favour of granting authorisation, afterdeletion of any information of a commercially confidentialnature.
The European Public Assessment Report (EPAR) shall include a
summary written in a manner that is understandable to the
public. The summary shall contain in particular a sectionrelating to the conditions of use of the medicinal product.
4. After a marketing authorisation has been granted, the
holder of the authorisation shall inform the Agency of thedates of actual placing on the market of the veterinarymedicinal product in Member States, taking into account thevarious presentations authorised.
The holder shall also notify the Agency if the product ceases to
be placed on the market, either temporarily or permanently.Such notification shall, other than in exceptional circum-stances, be made no less than 2 months before the interruptionin the placing of the product on the market.Upon request by the Agency, particularly in the context ofpharmacovigilance, the marketing authorisation holder shallprovide the Agency with all data relating to the volume ofsales of the medicinal product at Community level, brokendown by Member State, and any data in the holder's possessionrelating to the volume of prescriptions.
Article 39
1. Without prejudice to paragraphs 4 and 5, a marketingauthorisation shall be valid for five years.
2. The marketing authorisation may be renewed after five
years on the basis of a re-evaluation by the Agency of therisk-benefit balance.
To this end, the marketing authorisation holder shall submit a
consolidated list of all documents submitted in respect ofquality, safety and efficacy, including all variations introducedsince the marketing authorisation was granted, at least sixmonths before the marketing authorisation ceases to be validin accordance with paragraph 1. The Agency may require theapplicant to submit the listed documents at any time.
3. Once renewed, the marketing authorisation shall be valid
for an unlimited period, unless the Commission decides, onjustified grounds relating to pharmacovigilance, to proceedwith one additional five-year renewal in accordance withparagraph 2.
4. Any authorisation which is not followed by the actual
placing of the medicinal product for veterinary use on theCommunity market within three years after authorisationshall cease to be valid.
5. When an authorised medicinal product previously placed
on the market is no longer actually present on the market forthree consecutive years, the authorisation shall cease to be
valid.
6. In exceptional circumstances and on public and/or animal
health grounds the Commission may grant exemptions from
the provisions of paragraphs 4 and 5. Such exemptions must
be duly justified.
7. In exceptional circumstances and following consultation
with the applicant, authorisation may be granted subject to arequirement for the applicant to introduce specific procedures,in particular concerning product safety, notification to therelevant authorities of any incident relating to its use, andaction to be taken. This authorisation may be granted onlyfor objective, verifiable reasons. Continuation of the author-isation shall be linked to the annual reassessment of theseconditions.EN 30.4.2004 Official Journal of the European Union L 136/17
IP/N/1/EU/U/2 
        - 19 -8. When an application is submitted for a marketing auth-
orisation in respect of veterinary medicinal products of majorinterest, particularly from the point of view of animal healthand from the viewpoint of therapeutic innovation, theapplicant may request an accelerated assessment procedure.The request shall be duly substantiated.
If the Committee for Medicinal Products for Veterinary Use
accepts the request, the time-limit laid down in Article 31(3),first subparagraph, shall be reduced to 150 days.
9. When adopting its opinion, the said Committee shall
include a proposal concerning the conditions for the
prescription or use of the veterinary medicinal products.
10. Veterinary medicinal products which have been auth-
orised in accordance with the provisions of this Regulation
shall benefit from the provisions on protection in Articles 13and 13a of Directive 2001/82/EC.
Article 40
The granting of authorisation shall not affect the civil or
criminal liability of the manufacturer or the holder of themarketing authorisation pursuant to the applicable nationallaw in Member States.
Chapter 2
Supervision and sanctions
Article 41
1. After an authorisation has been granted in accordancewith this Regulation, the holder of the marketing authorisationshall, in respect of the methods of manufacture and controlprovided for in Article 12(3)(d) and (i) of Directive2001/82/EC, take account of technical and scientific progress
and make any variations that may be required to enable the
medicinal products to be manufactured and checked by meansof generally accepted scientific methods. He shall apply forapproval of these variations in accordance with this Regulation.
2. The competent authority of a Member State or the
Agency may require the holder of the marketing authorisationto provide substances in sufficient quantities for theperformance of tests to detect the presence of residues of theveterinary medicinal products concerned in foodstuffs ofanimal origin.
3. At the request of the competent authority of a Member
State or the Agency, the holder of the marketing authorisationshall provide technical expertise to facilitate the implemen-tation of the analytical method for detecting residues ofveterinary medicinal products by the Community referencelaboratory or, where appropriate, national reference labora-tories designated in accordance with Council Directive96/23/EC of 29 April 1996 on measures to monitor certainsubstances and residues thereof in live animals and animalproducts (
1).
4. The holder of the marketing authorisation shall forthwith
supply to the Agency, the Commission and the Member States
any new information which might entail the variation of theparticulars or documents referred to in Articles 12(3), 13, 13a,13b and 14 of Directive 2001/82/EC, in Annex I thereto, or inArticle 34(4) of this Regulation.
He shall forthwith inform the Agency, the Commission and the
Member States of any prohibition or restriction imposed by thecompetent authorities of any country in which the veterinarymedicinal product is marketed and of any other newinformation which might influence the evaluation of thebenefits and risks of the veterinary medicinal productconcerned.
In order that the risk-benefit balance may be continuously
assessed, the Agency may at any time ask the holder of themarketing authorisation to forward data justifying that the risk-benefit balance remains favourable.
5. If the holder of the marketing authorisation for the
veterinary medicinal product proposes to make any variation
of the particulars and documents referred to in paragraph 4, he
shall submit the relevant application to the Agency.
6. The Commission shall, after consulting the Agency, adopt
appropriate provisions for the examination of variations tomarketing authorisations in the form of a regulation inaccordance with the procedure referred to in Article 87(2).
Article 42
The applicant or the holder of a marketing authorisation shallbe responsible for the accuracy of the documents and of thedata submitted.
Article 43
1. In the case of veterinary medicinal products manu-factured within the Community, the supervisory authoritiesshall be the competent authorities of the Member State orMember States which granted the manufacturing authorisationprovided for in Article 44(1) of Directive 2001/82/EC inrespect of the manufacture of the medicinal product concerned.EN L 136/18 Official Journal of the European Union 30.4.2004
(1) OJ L 125, 23.5.1996, p. 10. Directive as amended by Regulation
(EC) No 806/2003 (OJ L 122, 16.5.2003, p. 1).
IP/N/1/EU/U/2 
        - 20 -2. In the case of veterinary medicinal products imported
from third countries, the supervisory authorities shall be thecompetent authorities of the Member State or Member Statesthat granted the authorisation provided for in Article 44(3) ofDirective 2001/82/EC to the importer, unless appropriateagreements have been made between the Community and theexporting country to ensure that those controls are carried outin the exporting country and that the manufacturer applies
standards of good manufacturing practice at least equivalent
to those laid down by the Community.
A Member State may request assistance from another Member
State or the Agency.
Article 44
1. The supervisory authorities shall be responsible forverifying on behalf of the Community that the holder of themarketing authorisation for the veterinary medicinal product or
the manufacturer or importer established within the
Community satisfies the requirements laid down in Titles IV,VII and VIII of Directive 2001/82/EC.
2. Where, in accordance with Article 90 of Directive
2001/82/EC, the Commission is informed of serious differencesof opinion between Member States as to whether the holder ofthe marketing authorisation for the veterinary medicinalproduct or a manufacturer or importer established within theCommunity satisfies the requirements referred to in paragraph1, the Commission may, after consultation with the MemberStates concerned, request an inspector from the supervisoryauthority to undertake a new inspection of the holder of themarketing authorisation, the manufacturer or the importer; theinspector in question shall be accompanied by two inspectorsfrom Member States which are not party to the dispute and/orby two experts nominated by the Committee for MedicinalProducts for Veterinary Use.
3. Subject to any agreements which may have been
concluded between the Community and third countries inaccordance with Article 43(2), the Commission may, uponreceipt of a reasoned request from a Member State or fromthe said Committee, or on its own initiative, require a manu-facturer established in a third country to submit to aninspection.
The inspection shall be undertaken by inspectors from the
Member State who possess the appropriate qualifications;they may be accompanied by a rapporteur or expertappointed by the said Committee. The report of the inspectorsshall be made available to the Commission, the Member Statesand the said Committee.
Article 45
1. Where the supervisory authorities or the competent auth-orities of any other Member State are of the opinion that themanufacturer or importer established within the Community isno longer fulfilling the obligations laid down in Title VII ofDirective 2001/82/EC, they shall forthwith inform theCommittee for Medicinal Products for Veterinary Use and theCommission, stating their reasons in detail and indicating thecourse of action proposed.
The same shall apply where a Member State or the
Commission considers that one of the measures envisaged inTitle VIII of Directive 2001/82/EC should be applied in respectof the veterinary medicinal product concerned or where thesaid Committee has delivered an opinion to that effect inaccordance with Article 30 of this Regulation.
2. The Commission shall request the opinion of the Agency
within a time-limit which it shall determine in the light of theurgency of the matter, in order to examine the reasonsadvanced. Whenever practicable, the holder of the marketingauthorisation for the medicinal product shall be invited toprovide oral or written explanations.
3. Following an opinion by the Agency, the Commission
shall adopt the necessary provisional measures, which shallbe applied immediately.
A final decision shall be adopted within six months, in
accordance with the procedure referred to in Article 87(3).
4. Where urgent action is essential to protect human or
animal health or the environment, a Member State may, onits own initiative or at the Commission's request, suspend theuse on its territory of a veterinary medicinal product which hasbeen authorised in accordance with this Regulation.
When it does so on its own initiative, the Member State shall
inform the Commission and the Agency of the reasons for itsaction at the latest on the next working day following thesuspension. The Agency shall inform the other MemberStates without delay. The Commission shall immediatelyinitiate the procedure provided for in paragraphs 2 and 3.
5. In this case, the Member State shall ensure that
health-care professionals are rapidly informed of its actionand the reasons for the action. Networks set up by professionalassociations may be used to this effect. Member States shallinform the Commission and the Agency of actions taken forthis purpose.
6. The suspensive measures referred to in paragraph 4 may
be maintained until such time as a definitive decision has beenreached in accordance with the procedure referred to in Article87(3).
7. The Agency shall, upon request, inform any person
concerned of the final decision and make the decisionpublicly accessible, immediately after it has been taken.EN 30.4.2004 Official Journal of the European Union L 136/19
IP/N/1/EU/U/2 
        - 21 -Chapter 3
Pharmacovigilance
Article 46
For the purpose of this Chapter, Article 77(2) of Directive
2001/82/EEC shall apply.
Article 47
The Agency, acting in close cooperation with the national
pharmacovigilance systems established in accordance withArticle 73 of Directive 2001/82/EC, shall receive all relevantinformation about suspected adverse reactions to veterinarymedicinal products which have been authorised by theCommunity in accordance with this Regulation. Where appro-priate the Committee for Medicinal Products for Veterinary Useshall, in accordance with Article 30 of this Regulation, draw upopinions on the measures necessary. These opinions shall bemade publicly accessible.
These measures may include amendments to the marketing
authorisation granted in accordance with Article 35. They
shall be adopted in accordance with the procedure referred
to in Article 87(3).
The holder of the marketing authorisation and the competent
authorities of the Member States shall ensure all relevantinformation about suspected adverse reactions to the veterinarymedicinal products authorised under this Regulation is broughtto the attention of the Agency in accordance with theprovisions of this Regulation. Animal owners and breedersshall be encouraged to communicate any adverse reaction tohealth-care professionals or to the competent national auth-orities responsible for pharmacovigilance.
Article 48
The holder of the marketing authorisation for a veterinarymedicinal product granted in accordance with the provisionsof this Regulation shall have permanently and continuously athis disposal an appropriately qualified person responsible for
pharmacovigilance.
That qualified person shall reside in the Community and shall
be responsible for the following:
(a) establishing and managing a system which ensures that
information about all suspected adverse reactions which
are reported to the personnel of the company and tomedical representatives is collected, evaluated and collated
so that it may be accessed at a single point within the
Community;
(b) preparing the reports referred to in Article 49(3) for the
competent authorities of the Member States and theAgency in accordance with the requirements of this Regu-
lation;
(c) ensuring that any request from the competent authorities
for the provision of additional information necessary for
the evaluation of the risks and benefits of a veterinarymedicinal product is answered fully and promptly,including the provision of information about the volumeof sales or prescriptions for the veterinary medicinalproduct concerned;
(d) providing the competent authorities with any other
information relevant to the evaluation of the risks andbenefits of a veterinary medicinal product, particularlyinformation concerning post-authorisation safety studies,including information regarding the validity of the with-drawal period or lack of expected efficacy or potentialenvironmental problems.
Article 49
1. The holder of the marketing authorisation for aveterinary medicinal product shall ensure that all suspectedserious adverse reactions, and adverse human reactions to aveterinary medicinal product authorised in accordance withthe provisions of this Regulation occurring within theCommunity which a health-care professional brings to hisattention are recorded and reported promptly to the MemberStates in the territory of which the incident occurred no laterthan 15 days following receipt of the information.
The holder of the marketing authorisation shall record any
other suspected serious adverse reactions and human adversereactions occurring within the Community, in accordance withthe guidelines referred to in Article 51, of which he mayreasonably be expected to be aware, and promptly notifyMember States in the territory of which the incidentoccurred and the Agency, and no later than 15 daysfollowing receipt of the information.
2. The holder of the marketing authorisation for a
veterinary medicinal product shall ensure that all suspectedserious unexpected adverse reactions, and adverse humanreactions, and any suspected transmission via a medicinalproduct of any infectious agent occurring in the territory ofa third country are reported promptly to the Member Statesand the Agency, and no later than 15 days following receipt ofthe information. The provisions for the reporting of suspectedunexpected adverse reactions which are not serious, whetheroccurring in the Community or in a third country, shall beadopted in accordance with the procedure referred to in Article87(2).
Save in exceptional circumstances, these reactions shall be
transmitted electronically in the form of a report and inaccordance with the guide referred to in Article 51.EN L 136/20 Official Journal of the European Union 30.4.2004
IP/N/1/EU/U/2 
        - 22 -3. The holder of the marketing authorisation for a
veterinary medicinal product shall maintain detailed recordsof all suspected adverse reactions occurring within or outsidethe Community which are reported to him.
Unless other requirements have been laid down as a condition
for the granting of the marketing authorisation by the
Community, these records shall be submitted, in the form of
a periodic safety update report, to the Agency and MemberStates immediately upon request or at least every six monthsafter authorisation until the placing on the market. Periodicsafety update reports shall also be submitted immediatelyupon request or at least every six months during the firsttwo years following the initial placing on the Communitymarket and once a year for the following two years. Thereafter,the reports shall be submitted at three-yearly intervals, orimmediately upon request.
These reports shall be accompanied by a scientific evaluation,
particularly of the risk-benefit balance of the medicinalproduct.
4. The Commission may lay down provisions to amend
paragraph 3 in view of experience gained with its operation.The Commission shall adopt any such provisions in accordancewith the procedure referred to in Article 87(2).
5. The holder of a marketing authorisation may not
communicate information relating to pharmacovigilanceconcerns to the general public in relation to its authorisedmedicinal product without giving prior or simultaneous notifi-cation to the Agency.
In any case, the marketing authorisation holder shall ensure
that such information is presented objectively and is not
misleading.
Member States shall take the necessary measures to ensure that
a marketing authorisation holder who fails to discharge theseobligations is subject to effective, proportionate and dissuasivepenalties.
Article 50
Each Member State shall ensure that all suspected seriousadverse reactions, and adverse human reactions, occurringwithin its territory to a veterinary medicinal product authorisedin accordance with the provisions of this Regulation which arebrought to its attention are recorded and reported promptly tothe Agency and the holder of the marketing authorisation forthe veterinary medicinal product, and no later than 15 daysfollowing receipt of the information.The Agency shall forward the information to the national phar-macovigilance systems set up in accordance with Article 73 ofDirective 2001/82/EC.
Article 51
The Commission, in consultation with the Agency, MemberStates and interested parties, shall draw up a guide on thecollection, verification and presentation of adverse-reactionreports. This guide shall contain, in particular, for the benefit
of health-care professionals, recommendations concerning the
communication of information on adverse reactions.
In accordance with this guide, holders of marketing authoris-
ations shall use the medical terminology accepted at inter-national level for the transmission of adverse-reaction reports.
The Agency, in consultation with the Member States and the
Commission, shall set up a data-processing network for therapid transmission of data between the competentCommunity authorities in the event of an alert relating tofaulty manufacture, serious adverse reactions and other phar-macovigilance data regarding veterinary medicinal productsauthorised in accordance with Article 5 of Directive2001/82/EC.
For a period of five years following the initial placing on the
market in the Community, the Agency may request that themarketing authorisation holder arrange for specific phar-macovigilance data to be collected from targeted groups ofanimals. The Agency shall state the reasons for the request.The marketing authorisation holder shall collate and assessthe data collected and submit it to the Agency for evaluation.
Article 52
The Agency shall cooperate with international organisationsconcerned with veterinary pharmacovigilance.
Article 53
The Agency and the Member States' competent authorities shall
cooperate to continuously develop pharmacovigilance systems
capable of achieving high standards of public health protection
for all medicinal products, regardless of routes of authorisation,including the use of collaborative approaches, to maximise useof resources available within the Community.
Article 54
Any amendment which may be necessary to update the
provisions of this Chapter in order to take account of scientificand technical progress shall be adopted in accordance with theprocedure referred to in Article 87(2).EN 30.4.2004 Official Journal of the European Union L 136/21
IP/N/1/EU/U/2 
        - 23 -TITLE IV
THE EUROPEAN MEDICINES AGENCY — RESPONSIBILITIES AND ADMINISTRATIVE STRUCTURE
Chapter 1
Tasks of the Agency
Article 55
A European Medicines Agency is hereby established.
The Agency shall be responsible for coordinating the existing
scientific resources put at its disposal by Member States for theevaluation, supervision and pharmacovigilance of medicinalproducts.
Article 56
1. The Agency shall comprise:
(a) the Committee for Medicinal Products for Human Use,
which shall be responsible for preparing the opinion of
the Agency on any question relating to the evaluation ofmedicinal products for human use;
(b) the Committee for Medicinal Products for Veterinary Use,
which shall be responsible for preparing the opinion of theAgency on any question relating to the evaluation ofmedicinal products for veterinary use;
(c) the Committee on Orphan Medicinal Products;
(d) the Committee on Herbal Medicinal Products;(e) a Secretariat, which shall provide technical, scientific and
administrative support for the committees and ensure
appropriate coordination between them;
(f) an Executive Director, who shall exercise the responsi-
bilities set out in Article 64;
(g) a Management Board, which shall exercise the responsi-
bilities set out in Articles 65, 66 and 67.
2. The committees referred to in paragraph 1(a) to (d) mayeach establish standing and temporary working parties. Thecommittees referred to in paragraph 1(a) and (b) mayestablish scientific advisory groups in connection with theevaluation of specific types of medicinal products ortreatments, to which the committee concerned may delegatecertain tasks associated with drawing up the scientific opinionsreferred to in Articles 5 and 30.
When establishing working parties and scientific advisory
groups, the committees shall in their rules of proceduresreferred to in Article 61(8) provide for:(a) the appointment of members of these working parties and
scientific advisory groups on the basis of the lists of expertsreferred to in the second subparagraph of Article 62(2);and
(b) consultation of these working parties and scientific advisory
groups.
3. The Executive Director, in close consultation with theCommittee for Medicinal Products for Human Use and theCommittee for Medicinal Products for Veterinary Use, shallset up the administrative structures and procedures allowingthe development of advice for undertakings, as referred to inArticle 57(1)(n), particularly regarding the development of newtherapies.
Each committee shall establish a standing working party with
the sole remit of providing scientific advice to undertakings.
4. The Committee for Medicinal Products for Human Use
and the Committee for Medicinal Products for Veterinary Use
may, if they consider it appropriate, seek guidance on
important questions of a general scientific or ethical nature.
Article 57
1. The Agency shall provide the Member States and theinstitutions of the Community with the best possible scientificadvice on any question relating to the evaluation of the quality,safety and efficacy of medicinal products for human orveterinary use which is referred to it in accordance with theprovisions of Community legislation relating to medicinalproducts.
To this end, the Agency, acting particularly through its
committees, shall undertake the following tasks:
(a) coordination of the scientific evaluation of the quality,
safety and efficacy of medicinal products which are
subject to Community marketing authorisation procedures;
(b) transmitting on request and making publicly available
assessment reports, summaries of product characteristics,
labels and package leaflets or inserts for these medicinalproducts;
(c) coordination of the supervision, under practical conditions
of use, of medicinal products which have been authorised
within the Community and the provision of advice on themeasures necessary to ensure the safe and effective use ofthese products, in particular by evaluation, coordination ofthe implementation of pharmacovigilance obligations andthe monitoring of such implementation;EN L 136/22 Official Journal of the European Union 30.4.2004
IP/N/1/EU/U/2 
        - 24 -(d) ensuring the dissemination of information on adverse
reactions to medicinal products authorised in the
Community, by means of a database permanentlyaccessible to all Member States; health-care professionals,marketing authorisation holders and the public shall haveappropriate levels of access to these databases, withpersonal data protection being guaranteed;
(e) assisting Member States with the rapid communication of
information concerning pharmacovigilance to health-care
professionals.
(f) distributing appropriate pharmacovigilance information to
the general public;
(g) advising on the maximum limits for residues of veterinary
medicinal products which may be accepted in foodstuffs of
animal origin in accordance with Regulation (EEC)No 2377/90;
(h) providing scientific advice on the use of antibiotics in
food-producing animals in order to minimise the
occurrence of bacterial resistance in the Community; thisadvice shall be updated when needed;
(i) coordinating the verification of compliance with the prin-
ciples of good manufacturing practice, good laboratory
practice, good clinical practice and the verification ofcompliance with pharmacovigilance obligations;
(j) upon request, providing technical and scientific support in
order to improve cooperation between the Community, its
Member States, international organisations and third
countries on scientific and technical issues relating to theevaluation of medicinal products, in particular in thecontext of discussions organised in the framework of inter-national conferences on harmonisation;
(k) recording the status of marketing authorisations for
medicinal products granted in accordance with
Community procedures;
(l) creating a database on medicinal products, to be accessible
to the general public, and ensuring that it is updated, and
managed independently of pharmaceutical companies; thedatabase shall facilitate the search for information alreadyauthorised for package leaflets; it shall include a section onmedicinal products authorised for the treatment ofchildren; the information provided to the public shall beworded in an appropriate and comprehensible manner;
(m) assisting the Community and Member States in the
provision of information to health-care professionals andthe general public about medicinal products evaluated bythe Agency;
(n) advising undertakings on the conduct of the various tests
and trials necessary to demonstrate the quality, safety andefficacy of medicinal products;
(o) checking that the conditions laid down in Community
legislation on medicinal products and in the marketingauthorisations are observed in the case of paralleldistribution of medicinal products authorised inaccordance with this Regulation;
(p) drawing up, at the Commission's request, any other
scientific opinion concerning the evaluation of medicinalproducts or the starting materials used in the manufactureof medicinal products;
(q) with a view to the protection of public health, compilation
of scientific information concerning pathogenic agents
which might be used in biological warfare, including theexistence of vaccines and other medicinal productsavailable to prevent, or to treat, the effects of such agents;
(r) coordination of the supervision of the quality of medicinal
products placed on the market by requesting testing ofcompliance with their authorised specifications by anOfficial Medicines Control Laboratory or by a laboratorythat a Member State has designated for that purpose;
(s) forwarding annually to the budgetary authority any
information relevant to the outcome of the evaluation
procedures.
2. The database provided for in paragraph 1(l) shall includethe summaries of product characteristics, the patient or userpackage leaflet and the information shown on the labelling.The database shall be developed in stages, priority beinggiven to medicinal products authorised under this Regulationand those authorised under Chapter 4 of Title III of Directive2001/83/EC and of Directive 2001/82/EC respectively. Thedatabase shall subsequently be extended to include anymedicinal product placed on the market within theCommunity.
Where appropriate, the database shall also include references to
data on clinical trials currently being carried out or alreadycompleted, contained in the clinical trials database providedfor in Article 11 of Directive 2001/20/EC. The Commissionshall, in consultation with the Member States, issue guidelineson data fields which could be included and which may beaccessible to the public.EN 30.4.2004 Official Journal of the European Union L 136/23
IP/N/1/EU/U/2 
        - 25 -Article 58
1. The Agency may give a scientific opinion, in the context
of cooperation with the World Health Organisation, for theevaluation of certain medicinal products for human useintended exclusively for markets outside the Community. Forthis purpose, an application shall be submitted to the Agencyin accordance with the provisions of Article 6. The Committeefor Medicinal Products for Human Use may, after consultingthe World Health Organisation, draw up a scientific opinion inaccordance with Articles 6 to 9. The provisions of Article 10shall not apply.
2. The said Committee shall establish specific procedural
rules for the implementation of paragraph 1, as well as forthe provision of scientific advice.
Article 59
1. The Agency shall take care to ensure early identification
of potential sources of conflict between its scientific opinionsand those of other bodies established under Community lawcarrying out a similar task in relation to issues of commonconcern.
2. Where the Agency identifies a potential source of
conflict, it shall contact the body concerned in order toensure that any relevant scientific information is shared andto identify the scientific points which potentially conflict.
3. Where there is a fundamental conflict over scientific
points and the body concerned is a Community agency or ascientific committee, the Agency and the body concerned shallwork together either to resolve the conflict or to submit a jointdocument to the Commission clarifying the scientific points ofconflict. This document shall be published immediately after itsadoption.
4. Save as otherwise provided in this Regulation, in
Directive 2001/83/EC or in Directive 2001/82/EC, wherethere is a fundamental conflict over scientific points and thebody concerned is a body in a Member State, the Agency andthe national body concerned shall work together either toresolve the conflict or to prepare a joint document clarifyingthe scientific points of conflict. This document shall be
published immediately after its adoption.
Article 60
At the request of the Commission, the Agency shall, in respect
of authorised medicinal products, collect any availableinformation on methods that Member States' competent auth-orities use to determine the added therapeutic value that anynew medicinal product provides.Article 61
1. Each Member State shall, after consultation of the
Management Board, appoint, for a three-year term whichmay be renewed, one member and one alternate to theCommittee for Medicinal Products for Human Use and onemember and one alternate to the Committee for MedicinalProducts for Veterinary Use.
The alternates shall represent and vote for the members in their
absence and may act as rapporteurs in accordance with Article62.
Members and alternates shall be chosen for their role and
experience in the evaluation of medicinal products forhuman and veterinary use as appropriate and shall representthe competent national authorities.
2. The committees may co-opt a maximum of five
additional members chosen on the basis of their specificscientific competence. These members shall be appointed for
a term of three years, which may be renewed, and shall not
have alternates.
With a view to the co-opting of such members, the committees
shall identify the specific complementary scientific competenceof the additional member(s). Co-opted members shall bechosen among experts nominated by Member States or theAgency.
3. The members of each Committee may be accompanied
by experts in specific scientific or technical fields.
4. The Executive Director of the Agency or his represen-
tative and representatives of the Commission shall be entitledto attend all meetings of the committees, working parties andscientific advisory groups and all other meetings convened bythe Agency or its committees.
5. In addition to their task of providing objective scientific
opinions to the Community and Member States on thequestions which are referred to them, the members of eachcommittee shall ensure that there is appropriate coordinationbetween the tasks of the Agency and the work of competentnational authorities, including the consultative bodiesconcerned with the marketing authorisation.
6. Members of the committees and experts responsible for
evaluating medicinal products shall rely on the scientific
evaluation and resources available to national marketing auth-
orisation bodies. Each competent national authority shallmonitor the scientific level and independence of the evaluationcarried out and facilitate the activities of nominated committeemembers and experts. Member States shall refrain from givingcommittee members and experts any instruction which isincompatible with their own individual tasks or with thetasks and responsibilities of the Agency.EN L 136/24 Official Journal of the European Union 30.4.2004
IP/N/1/EU/U/2 
        - 26 -7. When preparing the opinion, each committee shall use its
best endeavours to reach a scientific consensus. If such aconsensus cannot be reached, the opinion shall consist of theposition of the majority of members and divergent positions,with the grounds on which they are based.
8. Each committee shall establish its own rules of procedure.
These rules shall, in particular, lay down:(a) procedures for appointing and replacing the Chairman;
(b) procedures relating to working parties and scientific
advisory groups; and
(c) a procedure for the urgent adoption of opinions,
particularly in relation to the provisions of this Regulation
on market surveillance and pharmacovigilance.
They shall enter into force after receiving a favourable opinion
from the Commission and the Management Board.
Article 62
1. Where, in accordance with the provisions of this Regu-lation, the Committee for Medicinal Products for Human Use,the Committee on Herbal Medicinal Products or the Committeefor Medicinal Products for Veterinary Use is required toevaluate a medicinal product, it shall appoint one of itsmembers to act as rapporteur for the coordination of theevaluation. The Committee concerned may appoint a secondmember to act as co-rapporteur.
When consulting the scientific advisory groups referred to in
Article 56(2), the Committee shall forward to them the draftassessment report(s) drawn up by the rapporteur or theco-rapporteur. The opinion issued by the scientific advisorygroup shall be forwarded to the chairman of the relevantCommittee in such a way as to ensure that the deadlines laiddown in Article 6(3) and Article 31(3) are met.
The substance of the opinion shall be included in the
assessment report published pursuant to Article 13(3) andArticle 38(3).
If there is a request for re-examination of one of its opinions,
the Committee concerned shall appoint a different rapporteurand, where necessary, a different co-rapporteur from thoseappointed for the initial opinion. The re-examinationprocedure may deal only with the points of the opinioninitially identified by the applicant and may be based onlyon the scientific data available when the Committee adoptedthe initial opinion. The applicant may request that theCommittee consult a scientific advisory group in connectionwith the re-examination.
2. Member States shall transmit to the Agency the names of
national experts with proven experience in the evaluation ofmedicinal products who would be available to serve onworking parties or scientific advisory groups of theCommittee for Medicinal Products for Human Use, theCommittee on Herbal Medicinal Products or the Committeefor Medicinal Products for Veterinary Use, together with anindication of their qualifications and specific areas of expertise.
The Agency shall keep an up-to-date list of accredited experts.
The list shall include the experts referred to in the firstsubparagraph and other experts appointed directly by theAgency. The list shall be updated.
3. The provision of services by rapporteurs or experts shall
be governed by a written contract between the Agency and theperson concerned, or where appropriate between the Agencyand his employer.
The person concerned, or his employer, shall be remunerated
in accordance with a scale of fees to be included in thefinancial arrangements established by the Management Board.
4. The performance of scientific services for which there are
several potential providers may result in a call for anexpression of interest, if the scientific and technical contextallows, and if it is compatible with the tasks of the Agency,in particular to ensure a high level of public health protection.
The Management Board shall adopt the appropriate procedures
on a proposal from the Executive Director.
5. The Agency or any of the committees referred to in
Article 56(1) may use the services of experts for thedischarge of other specific tasks for which they are responsible.
Article 63
1. The membership of the committees referred to in Article56(1) shall be made public. When each appointment ispublished, the professional qualifications of each membershall be specified.EN 30.4.2004 Official Journal of the European Union L 136/25
IP/N/1/EU/U/2 
        - 27 -2. Members of the Management Board, members of the
committees, rapporteurs and experts shall not have financialor other interests in the pharmaceutical industry which couldaffect their impartiality. They shall undertake to act in thepublic interest and in an independent manner, and shallmake an annual declaration of their financial interests. Allindirect interests which could relate to this industry shall beentered in a register held by the Agency which is accessible to
the public, on request, at the Agency's offices.
The Agency's code of conduct shall provide for the implemen-
tation of this Article with particular reference to the acceptanceof gifts.
Members of the Management Board, members of the
committees, rapporteurs and experts who participate inmeetings or working groups of the Agency shall declare, ateach meeting, any specific interests which could be consideredto be prejudicial to their independence with respect to theitems on the agenda. These declarations shall be madeavailable to the public.
Article 64
1. The Executive Director shall be appointed by theManagement Board, on a proposal from the Commission, fora period of five years on the basis of a list of candidatesproposed by the Commission following a call for expressionsof interest published in the Official Journal of the European Union
and elsewhere. Before appointment, the candidate nominatedby the Management Board shall be invited forthwith to make astatement to the European Parliament and to answer anyquestions put by its Members. His mandate may be renewedonce. The Management Board may, upon a proposal from theCommission, remove the Executive Director from his post.
2. The Executive Director shall be the legal representative of
the Agency. He shall be responsible:
(a) for the day-to-day administration of the Agency;(b) for managing all the Agency resources necessary for
conducting the activities of the committees referred to in
Article 56(1), including making available appropriate
scientific and technical support;
(c) for ensuring that the time-limits laid down in Community
legislation for the adoption of opinions by the Agency arecomplied with;
(d) for ensuring appropriate coordination between the
committees referred to in Article 56(1);
(e) for the preparation of the draft statement of estimates of
the Agency's revenue and expenditure, and execution of itsbudget;(f) for all staff matters;
(g) for providing the secretariat for the Management Board.
3. Each year the Executive Director shall submit a draft
report covering the activities of the Agency in the previousyear and a draft work programme for the coming year tothe Management Board for approval, making a distinctionbetween the Agency's activities concerning medicinalproducts for human use, those concerning herbal medicinalproducts and those concerning veterinary medicinal products.
The draft report covering the activities of the Agency in the
previous year shall include information about the number ofapplications evaluated within the Agency, the time taken forcompletion of the evaluation and the medicinal products auth-orised, rejected or withdrawn.
Article 65
1. The Management Board shall consist of one represen-tative of each Member State, two representatives of theCommission and two representatives of the EuropeanParliament.
In addition, two representatives of patients' organisations, one
representative of doctors' organisations and one representative
of veterinarians' organisations shall be appointed by theCouncil in consultation with the European Parliament on thebasis of a list drawn up by the Commission which includesappreciably more names than there are posts to be filled. Thelist drawn up by the Commission shall be forwarded to theEuropean Parliament, together with the relevant backgrounddocuments. As quickly as possible, and within three monthsof notification, the European Parliament may submit its viewsfor consideration to the Council, which shall then appoint theManagement Board.
The members of the Management Board shall be appointed in
such a way as to guarantee the highest levels of specialistqualifications, a broad spectrum of relevant expertise and thebroadest possible geographic spread within the EuropeanUnion.
2. The members of the Management Board shall be
appointed on the basis of their relevant expertise inmanagement and, if appropriate, experience in the field ofmedicinal products for human or veterinary use.
3. Each Member State and the Commission shall appoint
their members of the Management Board as well as analternate who will replace the member in his absence andvote on his behalf.EN L 136/26 Official Journal of the European Union 30.4.2004
IP/N/1/EU/U/2 
        - 28 -4. The term of office of the representatives shall be three
years. The term of office may be renewed.
5. The Management Board shall elect its Chairman from
among its members.
The term of office of the Chairman shall be three years and
shall expire when he ceases to be a member of theManagement Board. The term of office may be renewed once.
6. Decisions of the Management Board shall be adopted by a
majority of two-thirds of its members.
7. The Management Board shall adopt its rules of procedure.8. The Management Board may invite the chairmen of the
scientific committees to attend its meetings, but they shall nothave the right to vote.
9. The Management Board shall approve the annual work
programme of the Agency programme and forward it to theEuropean Parliament, the Council, the Commission and theMember States.
10. The Management Board shall adopt the annual report
on the Agency's activities and forward it by 15 June at thelatest to the European Parliament, the Council, theCommission, the European Economic and Social Committee,the Court of Auditors and the Member States.
Article 66
The Management Board shall:
(a) adopt an opinion on the rules of procedures of the
Committee for Medicinal Products for Human Use and
the Committee for Medicinal Products for Veterinary Use(Article 61);
(b) adopt procedures for the performance of scientific services
(Article 62);
(c) appoint the Executive Director (Article 64);
(d) adopt the annual work programme and forward it to the
European Parliament, the Council, the Commission and the
Member States (Article 65);
(e) approve the annual report on the Agency's activities and
forward it by 15 June at the latest to the European
Parliament, the Council, the Commission, the EuropeanEconomic and Social Committee, the Court of Auditorsand the Member States (Article 65);
(f) adopt the budget of the Agency (Article 67);(g) adopt the internal financial provisions (Article 67);
(h) adopt provisions implementing the Staff Regulations
(Article 75);
(i) develop contacts with stakeholders and stipulate the
conditions applicable (Article 78);
(j) adopt provisions for providing assistance to pharmaceutical
companies (Article 79);
(k) adopt rules to ensure the availability to the public of
information concerning the authorisation or supervision
of medicinal products (Article 80).
Chapter 2
Financial Provisions
Article 67
1. Estimates of all the revenue and expenditure of theAgency shall be prepared for each financial year, correspondingto the calendar year, and shall be shown in the budget of theAgency.
2. The revenue and expenditure shown in the budget shall
be in balance.
3. The Agency's revenue shall consist of a contribution from
the Community and fees paid by undertakings for obtainingand maintaining Community marketing authorisations and forother services provided by the Agency.
The European Parliament and the Council (hereinafter referred
to as ‘the budgetary authority’) shall re-examine, whennecessary, the level of the Community contribution on thebasis of an evaluation of needs and taking account of thelevel of fees.
4. Activities relating to pharmacovigilance, to the operation
of communications networks and to market surveillance shallreceive adequate public funding commensurate with the tasksconferred.
5. The expenditure of the Agency shall include staff remun-
eration, administrative and infrastructure costs, and operatingexpenses as well as expenses resulting from contracts enteredinto with third parties.
6. Each year the Management Board, on the basis of a draft
drawn up by the Executive Director, shall produce an estimateof revenue and expenditure for the Agency for the followingfinancial year. This estimate, which shall include a draft estab-lishment plan, shall be forwarded by the Management Board tothe Commission by 31 March at the latest.EN 30.4.2004 Official Journal of the European Union L 136/27
IP/N/1/EU/U/2 
        - 29 -7. The estimate shall be forwarded by the Commission to
the budgetary authority together with the preliminary draftgeneral budget of the European Union.
8. On the basis of the estimate, the Commission shall enter
in the preliminary draft general budget of the European Union
the estimates it deems necessary for the establishment plan and
the amount of the subsidy to be charged to the general budget,which it shall place before the budgetary authority inaccordance with Article 272 of the Treaty.
9. The budgetary authority shall authorise the appro-
priations for the subsidy to the Agency.
The budgetary authority shall adopt the establishment plan for
the Agency.
10. The budget shall be adopted by the Management Board.
It shall become final following final adoption of the general
budget of the European Union. Where appropriate, it shall be
adjusted accordingly.
11. Any modification of the establishment plan and of the
budget shall be the subject of an amending budget, which isforwarded for the purposes of information to the budgetaryauthority.
12. The Management Board shall, as soon as possible, notify
the budgetary authority of its intention to implement anyproject which may have significant financial implications forthe funding of its budget, in particular any projects relating toproperty such as the rental or purchase of buildings. It shallinform the Commission thereof.
Where a branch of the budgetary authority has notified its
intention to deliver an opinion, it shall forward its opinionto the Management Board within a period of six weeks fromthe date of notification of the project.
Article 68
1. The Executive Director shall implement the budget of the
Agency.
2. By 1 March at the latest following each financial year, the
Agency's accounting officer shall communicate the provisionalaccounts to the Commission's accounting officer together witha report on the budgetary and financial management for thatfinancial year. The Commission's accounting officer shallconsolidate the provisional accounts of the institutions anddecentralised bodies in accordance with Article 128 of theFinancial Regulation applicable to the general budget of theEuropean Communities (
1) (hereinafter referred to as the
‘general Financial Regulation’).3. By 31 March at the latest following each financial year,
the Commission's accounting officer shall submit the Agency'sprovisional accounts to the Court of Auditors, together with areport on the budgetary and financial management for thatfinancial year. The report on the budgetary and financialmanagement for the financial year shall also be forwarded tothe European Parliament and the Council.
4. On receipt of the Court of Auditors' observations on the
Agency's provisional accounts, pursuant to Article 129 of thegeneral Financial Regulation, the Executive Director shall drawup the Agency's final accounts under his own responsibilityand submit them to the Management Board for an opinion.
5. The Management Board of the Agency shall deliver an
opinion on the Agency's final accounts.
6. The Executive Director shall, by 1 July at the latest
following each financial year, forward the final accounts tothe European Parliament, the Council, the Commission andthe Court of Auditors, together with the Management Board'sopinion.
7. The final accounts shall be published.8. The Agency's Executive Director shall send the Court of
Auditors a reply to its observations by 30 September at thelatest. He shall also send this reply to the Management Board.
9. The Executive Director shall submit to the European
Parliament, at the latter's request, any information requiredfor the smooth application of the discharge procedure forthe financial year in question, as laid down in Article 146(3)of the general Financial Regulation.
10. The European Parliament, on a recommendation from
the Council acting by a qualified majority, shall, before 30 Aprilof year N + 2, give a discharge to the Executive Director inrespect of the implementation of the budget for year N.
11. The financial rules applicable to the Agency shall be
adopted by the Management Board after the Commission hasbeen consulted. They may not depart from Commission Regu-lation (EC, Euratom) No 2343/2002 of 19 November 2002 onthe framework Financial Regulation for the bodies referred toin Article 185 of Council Regulation (EC, Euratom)No 1605/2002 on the Financial Regulation applicable to thegeneral budget of the European Communities (
2), unless
specifically required for the Agency's operation and with theCommission's prior consent.EN L 136/28 Official Journal of the European Union 30.4.2004
(1) Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002
on the Financial Regulation applicable to the general budget of the
European Communities (OJ L 248, 16.9.2002, p. 1). (2) OJ L 357, 31.12.2002, p. 72.
IP/N/1/EU/U/2 
        - 30 -Article 69
1. In order to combat fraud, corruption and other unlawful
activities the provisions of Regulation (EC) No 1073/1999 ofthe European Parliament and of the Council of 25 May 1999concerning investigations conducted by the EuropeanAnti-Fraud Office (OLAF) (
1) shall apply without restriction.
2. The Agency shall accede to the InterinstitutionalAgreement of 25 May 1999 concerning internal investigationsby the European Anti-Fraud Office (OLAF) and shall issue,without delay, the appropriate provisions applicable to all theemployees of the Agency.
Article 70
1. The structure and the level of the fees referred to inArticle 67(3) shall be established by the Council acting underthe conditions provided for by the Treaty on a proposal fromthe Commission, once the Commission has consulted organi-sations representing the interests of the pharmaceuticalindustry at Community level.
2. However, provisions shall be adopted in accordance with
the procedure referred to in Article 87(2), establishing thecircumstances in which small and medium-sized enterprisesmay pay reduced fees, defer payment of the fee, or receiveadministrative assistance.
Chapter 3
General Provisions governing the Agency
Article 71
The Agency shall have legal personality. In all Member States it
shall enjoy the most extensive legal capacity accorded to legalpersons under their laws. It may in particular acquire ordispose of movable and immovable property and may be aparty to legal proceedings.
Article 72
1. The contractual liability of the Agency shall be governed
by the law applicable to the contract in question. The Court of
Justice of the European Communities shall have jurisdictionpursuant to any arbitration clause contained in a contractconcluded by the Agency.
2. In the case of non-contractual liability, the Agency shall,
in accordance with the general principles common to the lawsof the Member States, make good any damage caused by it orby its servants in the performance of their duties.The Court of Justice shall have jurisdiction in any disputerelating to compensation for any such damage.
3. The personal liability of its servants towards the Agency
shall be governed by the relevant rules applying to the staff ofthe Agency.
Article 73
Regulation (EC) No 1049/2001 of the European Parliament andof the Council of 30 May 2001 regarding public access toEuropean Parliament, Council and Commission documents (
2)
shall apply to documents held by the Agency.
The Agency shall set up a register pursuant to Article 2(4) of
Regulation (EC) No 1049/2001 to make available alldocuments that are publicly accessible pursuant to this Regu-lation.
The Management Board shall adopt the arrangements for
implementing Regulation (EC) No 1049/2001 within sixmonths of entry into force of this Regulation.
Decisions taken by the Agency pursuant to Article 8 of Regu-
lation (EC) No 1049/2001 may give rise to the lodging of acomplaint with the Ombudsman or form the subject of anaction before the Court of Justice, under the conditions laiddown in Articles 195 and 230 of the Treaty respectively.
Article 74
The Protocol on the Privileges and Immunities of the EuropeanCommunities shall apply to the Agency.
Article 75
The staff of the Agency shall be subject to the rules and regu-lations applicable to officials and other staff of the EuropeanCommunities. In respect of its staff, the Agency shall exercisethe powers which have been devolved to the appointingauthority.
The Management Board, in agreement with the Commission,
shall adopt the necessary implementing provisions.
Article 76
Members of the Management Board, members of thecommittees referred to in Article 56(1), and experts andofficials and other servants of the Agency, shall be required,even after their duties have ceased, not to disclose informationof the kind covered by the obligation of professional secrecy.EN 30.4.2004 Official Journal of the European Union L 136/29
(1) OJ L 136, 31.5.1999, p. 1. (2) OJ L 145, 31.5.2001, p. 43.
IP/N/1/EU/U/2 
        - 31 -Article 77
The Commission may, in agreement with the Management
Board and the relevant committee, invite representatives ofinternational organisations with an interest in the harmon-isation of regulations applicable to medicinal products toparticipate as observers in the work of the Agency. Theconditions for participation shall be determined beforehandby the Commission.
Article 78
1. The Management Board shall, in agreement with the
Commission, develop appropriate contacts between theAgency and the representatives of the industry, consumersand patients and the health professions. These contacts mayinclude the participation of observers in certain aspects of theAgency's work, under conditions determined beforehand by the
Management Board, in agreement with the Commission.
2. The committees referred to in Article 56(1) and any
working parties and scientific advisory groups established inaccordance with that Article shall in general matters establishcontacts, on an advisory basis, with parties concerned with the
use of medicinal products, in particular patient organisations
and health-care professionals' associations. Rapporteursappointed by these committees may, on an advisory basis,establish contacts with representatives of patient organisationsand health-care professionals' associations relevant to the indi-cation of the medicinal product concerned.
Article 79
The Management Board shall, in the case of veterinarymedicinal products which have limited markets, or in thecase of veterinary medicinal products intended for diseaseswith a regional distribution, adopt the necessary measures toprovide assistance to companies at the time of submission oftheir applications.
Article 80
To ensure an appropriate level of transparency, the
Management Board, on the basis of a proposal by theExecutive Director and in agreement with the Commission,shall adopt rules to ensure the availability to the public of
regulatory, scientific or technical information concerning the
authorisation or supervision of medicinal products which is notof a confidential nature.
The internal rules and procedures of the Agency, its
committees and its working groups shall be made availableto the public at the Agency and on the Internet.
TITLE V
GENERAL AND FINAL PROVISIONS
Article 81
1. All decisions to grant, refuse, vary, suspend, withdraw or
revoke a marketing authorisation which are taken inaccordance with this Regulation shall state in detail thereasons on which they are based. Such decisions shall benotified to the party concerned.
2. An authorisation to place a medicinal product governed
by this Regulation on the market shall not be granted, refused,varied, suspended, withdrawn or revoked except through theprocedures and on the grounds set out in this Regulation.
Article 82
1. Only one authorisation may be granted to an applicantfor a specific medicinal product.
However, the Commission shall authorise the same applicant to
submit more than one application to the Agency for thatmedicinal product when there are objective verifiable reasonsrelating to public health regarding the availability of medicinalproducts to health-care professionals and/or patients, or forco-marketing reasons.
2. As regards medicinal products for human use, Article
98(3) of Directive 2001/83/EC shall apply to medicinalproducts authorised under this Regulation.3. Without prejudice to the unique, Community nature ofthe content of the documents referred to in Article 9(4)(a), (b),(c) and (d) and in Article 34(4)(a) to (e), this Regulation shallnot prohibit the use of two or more commercial designs for agiven medicinal product covered by a single authorisation.
Article 83
1. By way of exemption from Article 6 of Directive2001/83/EC Member States may make a medicinal productfor human use belonging to the categories referred to inArticle 3(1) and (2) of this Regulation available for compas-sionate use.
2. For the purposes of this Article, ‘compassionate use’ shall
mean making a medicinal product belonging to the categories
referred to in Article 3(1) and (2) available for compassionatereasons to a group of patients with a chronically or seriouslydebilitating disease or whose disease is considered to be life-threatening, and who can not be treated satisfactorily by anauthorised medicinal product. The medicinal productconcerned must either be the subject of an application for amarketing authorisation in accordance with Article 6 of thisRegulation or must be undergoing clinical trials.EN L 136/30 Official Journal of the European Union 30.4.2004
IP/N/1/EU/U/2 
        - 32 -3. When a Member State makes use of the possibility
provided for in paragraph 1 it shall notify the Agency.
4. When compassionate use is envisaged, the Committee for
Medicinal Products for Human Use, after consulting the manu-facturer or the applicant, may adopt opinions on theconditions for use, the conditions for distribution and thepatients targeted. The opinions shall be updated on a regularbasis.
5. Member States shall take account of any available
opinions.
6. The Agency shall keep an up-to-date list of the opinions
adopted in accordance with paragraph 4, which shall bepublished on its website. Article 24(1) and Article 25 shallapply mutatis mutandis .
7. The opinions referred to in paragraph 4 shall not affect
the civil or criminal liability of the manufacturer or of theapplicant for marketing authorisation.
8. Where a compassionate use programme has been set up,
the applicant shall ensure that patients taking part also haveaccess to the new medicinal product during the period betweenauthorisation and placing on the market.
9. This Article shall be without prejudice to Directive
2001/20/EC and to Article 5 of Directive 2001/83/EC.
Article 84
1. Without prejudice to the Protocol on the Privileges and
Immunities of the European Communities, each Member Stateshall determine the penalties to be applied for infringement ofthe provisions of this Regulation or the regulations adoptedpursuant to it and shall take all measures necessary for theirimplementation. The penalties shall be effective, proportionateand dissuasive.
Member States shall inform the Commission of these
provisions no later than 31 December 2004. They shallnotify any subsequent alterations as soon as possible.
2. Member States shall inform the Commission immediately
of any litigation instituted for infringement of this Regulation.
3. At the Agency's request, the Commission may impose
financial penalties on the holders of marketing authorisationsgranted under this Regulation if they fail to observe certainobligations laid down in connection with the authorisations.The maximum amounts as well as the conditions and methodsfor collection of these penalties shall be laid down inaccordance with the procedure referred to in Article 87(2).
The Commission shall publish the names of the marketing
authorisation holders involved and the amounts of and
reasons for the financial penalties imposed.
Article 85
This Regulation shall not affect the competences vested in the
European Food Safety Authority created by Regulation (EC)No 178/2002 (
1).
Article 86
At least every ten years, the Commission shall publish a generalreport on the experience acquired as a result of the operationof the procedures laid down in this Regulation, in Chapter 4 ofTitle III of Directive 2001/83/EC and in Chapter 4 of Title III ofDirective 2001/82/EC.
Article 87
1. The Commission shall be assisted by the StandingCommittee on Medicinal Products for Human Use set up byArticle 121 of Directive 2001/83/EC and by the StandingCommittee on Veterinary Medicinal Products set up byArticle 89 of Directive 2001/82/EC.
2. Where reference is made to this paragraph, Articles 5 and
7 of Decision 1999/468/EC shall apply, having regard to theprovisions of Article 8 thereof.
The period laid down in Article 5(6) of Decision 1999/468/EC
shall be set at three months.
3. Where reference is made to this paragraph, Articles 4 and
7 of Decision 1999/468/EC shall apply, having regard to theprovisions of Article 8 thereof.
The period laid down in Article 4(3) of Decision 1999/468/EC
shall be set at one month.
4. The committees shall adopt their Rules of Procedure.EN 30.4.2004 Official Journal of the European Union L 136/31
(1) Regulation (EC) No 178/2002 of the European Parliament and of
the Council of 28 January 2002 laying down the general principles
and requirements of food law, establishing the European FoodSafety Authority and laying down procedures in matters of foodsafety (OJ L 31, 1.2.2002, p. 1).
IP/N/1/EU/U/2 
        - 33 -Article 88
Regulation (EEC) No 2309/93/EC is hereby repealed.
References to the repealed Regulation shall be construed as
references to this Regulation.
Article 89
The periods of protection provided for in Articles 14(11) and39(10) shall not apply to reference medicinal products forwhich an application for authorisation has been submitted
before the date referred to in Article 90, second paragraph.
Article 90
This Regulation shall enter into force on the twentieth day
following that of its publication in the Official Journal of the
European Union .
By way of derogation from the first paragraph, Titles I, II, IIIand V shall apply from 20 November 2005 and point 3, fifthand sixth indent of the Annex shall apply from 20 May 2008.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Strasbourg 31 March 2004.
For the European Parliament
The President
P. COXFor the Council
The President
D. ROCHEEN L 136/32 Official Journal of the European Union 30.4.2004
IP/N/1/EU/U/2 
        - 34 -ANNEX
MEDICINAL PRODUCTS TO BE AUTHORISED BY THE COMMUNITY
1. Medicinal products developed by means of one of the following biotechnological processes:
— recombinant DNA technology,
— controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including
transformed mammalian cells,
— hybridoma and monoclonal antibody methods.
2. Medicinal products for veterinary use intended primarily for use as performance enhancers in order to promote the
growth of treated animals or to increase yields from treated animals.
3. Medicinal products for human use containing a new active substance which, on the date of entry into force of this
Regulation, was not authorised in the Community, for which the therapeutic indication is the treatment of any of the
following diseases:
— acquired immune deficiency syndrome,
— cancer,— neurodegenerative disorder,
— diabetes,
and with effect from 20 May 2008— auto-immune diseases and other immune dysfunctions,
— viral diseases.
After 20 May 2008, the Commission, having consulted the Agency, may present any appropriate proposal modifying
this point and the Council shall take a decision on that proposal by qualified majority.
4. Medicinal products that are designated as orphan medicinal products pursuant to Regulation (EC) No 141/2000.EN 30.4.2004 Official Journal of the European Union L 136/33
IP/N/1/EU/U/2 
        - 35 -